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A tyrosine hydroxylase coded by orf13 of the anthramycin biosynthesis gene 
cluster is proposed to catalyze the ortho-hydroxylation of L-tyrosine to L-DOPA as the 
initial step of a unique transformation to the hydropyrrole moiety found in anthramycin. 
The sequence of Orf13 is not similar to any known characterized proteins, nor does it 
contain conserved domains or motifs characteristic of enzymes performing aromatic 
hydroxylation. The lack of information for this common enzymatic reaction suggests the 
identification of a new class of tyrosine hydroxylases which may have novel cofactor 
requirements, novel folds and/or chemical mechanisms. 
Heme B has been identified in purified Orf13 and full heme B occupancy is 
achieved during expression with iron (III) citrate in E. coli. Maximal L-tyrosine to L-
DOPA conversion is observed in the presence of hydrogen peroxide (H2O2). This 
confirmed heme B as the required catalytic cofactor and the putative function of Orf13 as 
a tyrosine hydroxylase. This information also classified Orf13 as a heme peroxidase. 
Spectroscopic data from a reduced-CO (g) spectrum of Orf13 and electron paramagnetic 
resonance of ferric-heme Orf13 are consistent with histidyl-ligated heme peroxidases. 
The steady-state kinetics of L-tyrosine hydroxylation show similar catalytic efficiency for 
L-tyrosine and H2O2. Orf13 has a secondary tyrosine hydroxylation activity in the 
presence of molecular oxygen (O2) and dihydroxyfumaric acid (DHFA), which is also 
found with histidyl-heme peroxidases.  
Orf13 is substrate specific and stereoselective for L-tyrosine. Turnover is only 
observed with para-substituted phenols but not with D-tyrosine, implicating the para-
phenol substituent is required for hydroxylation. Although the catalytic requirements of 
heme B and H2O2 are in agreement with heme peroxidases, the resulting hydroxylated 
product (L-DOPA) by a H2O2 dependent pathway is unprecedented. Heme dependent 
aromatic hydroxylation is typically catalyzed by cytochrome P450s through an O2 
dependent pathway. Mechanistic investigation of Orf13 revealed H2O2 as the oxygen 
source in a labeling study using H2
18
O2. A proposed mechanism of L-tyrosine 
hydroxylation is suggested to proceed through an oxygen rebound mechanism similar to 
cytochrome P450 aromatic hydroxylation. Therefore, Orf13 represents a new class of 
heme-histidyl ligated H2O2 dependent hydroxylases and is the first identified bacterial 
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Chapter 1: Introduction to the discovery and proposed function of 
Orf13 as an L-tyrosine hydroxylase 
 
 
1.1 Pyrrolo[1,4]benzodiazepines (PBDs) are natural products of pharmaceutical 
interest 
The worldwide leading cause of death is cancer, accounting for 7.6 million deaths 
in 2008 (1). Nearly half of the currently approved drugs to treat cancer are natural 
products (NPs), such as taxol (generic name: paclitaxel), or have been derived from NPs 
(2). The discovery and development of new chemotherapies to treat cancer rely heavily 
on NP drug discovery, owing to the extraordinary chemical diversity and biological 
activities of NPs (2). However, fundamental challenges precluding the clinical use of NPs 
as potential chemotherapeutic agents include compound availability, target selectivity and 
specificity, and chemical potency relative to undesirable side effects and toxicity. 
Additionally, chemical synthesis of NPs or NP analogues is not always feasible with 
current synthetic methodologies due to chemically labile groups, achieving correct 
stereochemistry and/or the overall complexity of the compound itself. Alternative 
approaches to overcome these challenges in order to develop effective chemotherapeutic 
agents are available through biosynthetic engineering and mutasynthetic strategies with 
the identification of NP biosynthetic gene clusters.  
A class of natural products of chemotherapeutic interest is the 
pyrrolo[1,4]benzodiazepines (PBDs). Produced by actinomyces as secondary metabolites, 
PBDs display anti-cancer biological activity through inhibition of transcription and 
replication processes by sequence selective alkylation of DNA (3). Since the discovery of 
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anthramycin in 1963 (4) (Figure 1-1A), 18 other naturally produced PBDs have been 
isolated and characterized, and more than 60 synthetic PBDs have been made (3, 5). A 
synthetic PBD noteworthy of mention is SJG-136 (Figure 1-1B). This PBD dimer has 
remarkable anti-cancer biological activity and is currently in Phase II trials for the 
treatment of ovarian cancer (5, 6).  
 
 
Figure 1-1. (A) The pyrrolo[1,4]benzodiazepine anthramycin; (B) the synthetic PBD 
dimer, SJG-136; (C) 9-deoxysibiromycin, a sibiromycin analogue, and the parent NP 
sibiromycin.  
 
Interest and initiative to develop more potent PBD analogues as potential 
chemotherapeutic agents to treat cancer stem from current knowledge of PBD structural-
activity relationships (3, 5) and the identification and characterization of the PBD 
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biosynthetic gene clusters of anthramycin (7), tomaymycin (8) and sibiromycin (9). A 
recent and encouraging example is the mutasynthesis of a sibiromycin analogue, 9-
deoxysibiromycin (Figure 1-1C). This PBD analogue shows increased anti-tumor activity 
and reduced cardiotoxicity without the hydroxyl group at position 9 that is present in 
sibiromycin, the parent natural product (10). 
The chemical scaffold of PBDs is a three ring system with two conserved features 
(Figure 1-2A): 1) an imine group at N10-C11, where DNA alkylation occurs at C11 and 
2) S-stereochemistry at C11a that creates a right-handed twist to the PBD core structure. 
The right-handed twist of the PBD core matches the right-handed twist of B-DNA, 
allowing for suitable binding in the minor groove (11) with subsequent nucleophilic 
attack by the exocyclic nitrogen of a guanine base (3) (Figure 1-2B). The chemical 
substituents of rings A and C, and saturation of ring C, vary among naturally produced 
PBDs and relate to their overall antimicrobial and/or anti-tumor biological activities (3). 
However, the key chemical attributes of PBDs contributing to their anti-tumor 
chemotherapeutic properties and potency are: 
1) The absence of chemical substituents at C9; bulky substitutions inhibit DNA 
binding and the C9 hydroxyl group has been attributed to cardiotoxicity (3, 10, 12). 
2) The presence of electron donating groups at C7 and C8; donation of electron 
density to the benzodiazepine ring system favors the biologically active imine form 
over the inactive carbinolamine form (3, 12). 
3) O-glycosylation at C7; enhancement of the DNA-binding affinity is the proposed 
interaction between the positively charged sibirosamine sugar moiety of 
sibiromycin and negatively charged phosphate backbone of DNA (3, 12). 
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4) C2-endo or exocyclic unsaturation; the internal or external double bond at C2 
flattens ring C to improve the binding and fit of the PBDs into the minor groove of 
DNA and is observed in PBDs with the greatest anti-tumor potency (12-15).  
 
 
Figure 1-2. (A) Common ring structure of PBDs; (B) Mechanism of PBD-DNA complex 
formation. 
 
1.2 Ring C of PBDs - a novel biosynthetic transformation of L-tyrosine to the 
hydropyrrole moiety. 
L-Tryptophan, L-tyrosine and L-methionine are the metabolic precursors and 
biosynthetic origins of anthramycin, tomaymycin and sibiromycin (Figure 1-3) (16, 17). 
The biosynthetic assembly of the PBD scaffold occurs by a nonribosomal peptide 
synthetase (NRPS) that links together an anthranilic acid moiety derived from L-







Figure 1-3. Labeling pattern of atoms in the metabolic precursors L-tryptophan (blue), L-
methionine (green) and L-tyrosine (red) found in the natural products of anthramycin, 
tomamycin and sibiromycin. Chorismate is the chemical precursor of the anthranilate 
moiety in tomamycin.  
 
The biosynthetic pathway for the unusual transformation of L-tyrosine to the 
hydropyrrole moiety has not been well characterized beyond establishing its metabolic 
origins, and to date is unique to the biosynthesis of PBDs (18, 19), lincosamides (20, 21) 
and hormaomycin (22). Similar to PBDs, lincosamides and hormaomycin are also natural 
products from actinomyces and have different biological activities based upon their 
chemical properties (Figure 1-4A). Lincosamides disrupt and inhibit protein synthesis 
(23) and hormaomycin is a despeptide with potent narrow-spectrum antibiotic activity 
(24). The final hydropyrrole moiety incorporated into PBDs, lincomycin A and 
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hormaomycin is varied due to the enzymes present in the respective biosynthetic 
pathways (7-9, 22, 25). However, the starting point of this pathway begins with the same 
metabolic precursor, L-tyrosine, in which the biosynthesis of the hydropyrrole moiety is 
proposed to proceed through L-DOPA by hydroxylation of L-tyrosine (Figure 1-4B).  
 
 
Figure 1-4. (A) The natural products anthramycin (a PBD), lincomycin A (a 
lincosamide), and hormaomycin with the hydropyrrole moiety highlighted red; (B) The 
proposed biosynthetic pathway for the hydropyrrole moiety found in PBDs, lincomycin A 
and hormaomycin.  
 
 
1.3 Precedence for the putative function of Orf13 as an L-tyrosine hydroxylase  
The first proposed step in the hydropyrrole moiety biosynthesis is L-tyrosine 
hydroxylation. Prior to the identification of PBD biosynthetic gene clusters (7-9), initial 
studies were performed to identify the function of enzymes in the hydropyrrole moiety 
biosynthetic pathway of lincomycin A (26, 27). The tyrosine hydroxylase function of 
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LmbB2 was first suggested from cell free extract studies with LmbB2 and LmbB1, a 
putative 2,3-extradiol dioxygenase (Figure 1-5) (27). Formation of a yellow product with 
an absorbance at 414 nm, later assigned to the cyclized imine 4-(3-carboxy-3-
oxopropenyl)2,3-dihydrophyrrole-2-carboxylic acid (26), was observed when the cell free 
extract of co-expressed LmbB2 and LmbB1 was provided L-tyrosine as the substrate. 
However, no conversion of L-tyrosine to the cyclized imine was observed with cell free 
extract containing only LmbB1. Additional study of purified LmbB1 only showed L-
DOPA conversion to the cyclized imine which confirmed the 2,3-extradiol dioxygenase 
function of LmbB1, and indicated LmbB2 to be the putative tyrosine hydroxylase (27).  
 
 
Figure 1-5. Initial biosynthetic steps of the hydropyrrole moiety in lincomycin A. 
 
Orf13, from the anthramycin biosynthetic gene cluster, is proposed to catalyze L-
tyrosine hydroxylation based on sequence homology with LmbB2 (7). This putative 
tyrosine hydroxylase also shares sequence homology with TomI and SibU from the PBD 
biosynthetic pathways of tomaymycin and sibiromycin, respectively, as well as HrmE 
from the hormaomycin biosynthetic pathway. Additional homologues were identified by 
searching the NCBI protein databank in a BLAST search using Orf13 as the protein 
query sequence (Table 1-1). However, no other similar proteins or conserved domains 
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resulted from the BLAST query to indicate that the function for this group of proteins is 
tyrosine hydroxylation. No further information is reported in the literature relating to the 
characterization of the identified homologues other than the preliminary studies with 
LmbB2 proposing the tyrosine hydroxylase function. The limited information available 
beyond the putative functional assignment of these tyrosine hydroxylases sparks interest 
in their characterization as they have the potential to define a new class of tyrosine 
hydroxylases.  
 















LmbB2 Streptomyces lincolnesis Lincomycin A 34/44 CAA55748 
SibU Streptosporangium 
sibiricum 




Tomaymycin 34/45 ACN39022 
HrmE Streptomyces 
griseoflavus 





 33/43 YP_003767687 




 64/76 ZP_09842397 
S_W007
c












 35/45 AEY93897 
a
 Orf13 of the anthramycin biosynthetic gene cluster (Streptomyces refuineus thermotolerans 
NRRL 3143; Accession No. ABW71844). 
 
  b
 Sequence analysis performed with Needleman-Wunsch Global Alignment; NCBI BLAST (28).  
c
 Designated abbreviation of putative tyrosine hydroxylase to indicate producer in this thesis.   
d







1.4 Enzymes catalyzing L-tyrosine hydroxylation and/or aromatic hydroxylation  
The chemical reaction of L-tyrosine to L-DOPA is an ortho-hydroxylation of an 
aromatic ring. Enzymes responsible for this type of reaction include tyrosinases and 
aromatic hydroxylases, which are considered monophenol monooxygenases (MMOs) 
catalyzing an oxygen transfer reaction in which 1 atom of molecular oxygen (O2) is 
inserted into an aromatic substrate. There are 5 distinct classes of MMOs defined 
primarily by their cofactor requirement  (29) (Table 1-2). These are the heme dependent 
cytochrome P450 enzymes (30) and heme peroxidases (29, 31), the di-iron hydroxylases 
(32), the non-heme iron pterin or α-ketoglutarate dependent monooxygenases (33), the 
type III copper dependent monooxygenases (34), and the metal free flavin dependent 
monooxygenases (29). Within the 5 classes of MMOs, the non-heme iron pterin and α-
ketoglutarate dependent enzymes are specific for the ortho-hydroxylation of L-tyrosine to 
L-DOPA and have a highly conserved 2-His-1-carboxylate triad catalytic motif (35). 
While on the other hand, aromatic hydroxylation observed with heme peroxidases is a 
secondary pathway dependent on molecular oxygen and dihydroxyfumaric acid (36, 37) 
that is separate from their main catalytic function of 2-sequential 1-electron oxidization 
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Flavin, metal free 
a
 Abbreviations: Dihydroxyfumaric acid (DHFA), tetrahydrobiopterin (BH4), alpha-
ketoglutarate (α-KG), flavin adenine dinucleotide (FAD), nicotinamide adenine dinucleotide 
(phosphate) (NAD(P)H).  
 
An initial indication of a possible cofactor requirement was not evident after 
analysis of the conserved residues in Orf13 from a multiple sequence alignment with its 
known homologues (Figure 1-6) compared against the 5 classes of MMOs. This poses an 
intriguing question as to the cofactor requirement for this putative tyrosine hydroxylase. 
The enzyme may require an already established cofactor for MMOs, a new cofactor or 
have no cofactor requirement at all. For all cases, this enzyme represents a new class 





Figure 1-6. Multiple sequence alignment of the putative tyrosine hydroxylases from 
actinomyces; Orf13 (S. refuineus; anthramycin), TomI (S. achromogenes; tomamycin), 
SibU (Streptosporangium sibiricum; sibiromycin), LmbB2 (S. lincolnesis; lincomycin A), 
HrmE (S. griseoflavus; hormaomycin), AMED_5527 (Amycolatopsis mediterranei; 
unknown NP), Shyg_5008 (S. hygroscopicus jinggangensis; unknown NP) and S_W007 
(S. sp.W007; unknown NP), and O3I_32261 (Norcardia brasiliensis; unknown NP). 
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1.5 Specific Aims  
 The intrigue and impetus to characterize the tyrosine hydroxylase involved in the 
first step of hydropyrrole biosynthesis in PBDs are centered on the possibility of 
identifying the first class of bacterial tyrosine hydroxylases and defining a new MMO 
class based on its resulting cofactor requirement, chemical mechanism and/or structural 
fold. The putative tyrosine hydroxylases available for characterization are SibU 
(Streptosporangium sibiricum), TomI (Streptomyces achromogenes) and Orf13 
(Streptomyces refuineus thermotolerans). Of these three, only Orf13 was selected for 
characterization since it originates from a thermophile and would likely be a more stable 
enzyme than SibU and TomI. The goal of my research was to characterize Orf13, the 
putative tyrosine hydroxylase from the anthramycin biosynthetic gene cluster, in order to 
determine the enzyme cofactor requirement for catalysis, confirm enzymatic function for 
L-tyrosine hydroxylation, perform steady-state kinetic analysis and begin initial 
mechanistic investigation of L-tyrosine hydroxylation based on the assigned enzyme 
classification. This dissertation specifically addresses the following:  
1) Enzyme purification of Orf13 and cofactor identification. This includes initial 
cloning and purification methods to obtain and maintain stable and active enzyme, 
while also describing the identification of a bound heme B cofactor.     
2) Functional characterization of Orf13 and classification as a heme peroxidase. 
Assessment of heme B as a catalytically required cofactor for tyrosine 
hydroxylation is addressed, in addition to the classification of Orf13 as a heme 
peroxidase based on reaction requirements, spectroscopic evidence and steady-state 
kinetic analysis.   
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3) Additional characterization of Orf13 as a heme peroxidase and initial investigation 
of the chemical mechanism of L-tyrosine hydroxylation. Further experimentation is 
described to define substrate specificity for aromatic hydroxylation, to identify the 
proximal (5
th
) heme-iron ligand and to identify the oxygen source for tyrosine 

























Orf13 (S. refuineus) is the proposed tyrosine hydroxylase from the anthramycin 
biosynthetic gene cluster. Protein purification must first be performed in order to identify 
the presence of a cofactor. The initial cloning, expression and purification of Orf13 is 
described. Alongside the development of the protein purification process, a bound 
cofactor was discovered and identified as heme B. The stoichiometry of heme B was 
evaluated and expression conditions were optimized to obtain fully occupied enzyme 
containing heme B.    
2.2 Experimental Procedures 
Materials. The pSMT3 vector was generously provided by Dr. Christopher D. 
Lima (Memorial Sloan-Kettering Cancer Center) (38), the pET24a vector was purchased 
from Novagen (Darmstadt, Germany) and the pCW vector and RP523 E. coli strain were 
generously donated by Professor Michael A. Marletta (University of California at 
Berkeley). Molecular cloning materials: restriction enzymes NdeI and HindIII were 
purchased from New England Biolabs (Ipswich, MA); dNTPs, Pfu DNA Polymerase, T4 
ligase and DNA molecular weight ladder were purchased from Fermentas (Ontario, 
Canada). All purification resins and protein molecular weight standards for the 
quaternary structure determination were purchased from G.E. Healthcare (Piscataway, 
NJ). Sodium phosphate, imidazole, sodium chloride, and D-lactose were purchased with 
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the highest purity from ThermoFisher Scientific (Fair Lawn, NJ). Dithiothreitol (DTT) 
and phenylmethanesulfonylfluoride (PMSF) were purchased from American 
Bioanalytical Inc. (Natick, MA). Glycerol, heme B, protoporphyrin IX (PPIX) and all 
other chemicals were purchased with the highest purity from Sigma Aldrich (St. Louis, 
MO). 
General Methods. DNA isolation was performed using the Fermentas GeneJet 
Plasmid Miniprep kit (Glen Burnie, MD). PCR amplifications were carried out using a 
PTC-200 DNA Engine Cycler (Bio-Rad). All DNA agarose gel electrophoresis was 
performed at 100 V using 1% (w/v) agarose gels with GeneRuler 1 Kb Plus DNA Ladder 
(Fermentas). All DNA restriction digestion and ligation reactions were performed 
according to the manufacturer’s protocol. All DNA sequencing was performed at the 
Institute for Bioscience & Biotechnology Research (IBBR) DNA Sequencing Facility 
(University of Maryland, College Park, MD). Bacterial transformations of plasmid 
constructs into E. coli were carried out with a MicroPulser Electroporator (Bio-Rad; 2500 
V, 1 mm gap cuvette) and plated on LB agar with kanamycin (50 µg/mL) antibiotic 
selectivity. Protein concentrations of Orf13 were determined at A280 nm using an 




 (pH 8.0, 25 °C)) that was 
calculated by quantitative amino acid analysis (AAA Service Laboratory; Damascus, 
Oregon). All protein electrophoresis was performed at 200 V with the Mini Protean 3 
Cell gel electrophoresis system (Bio-Rad) using denaturing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels (12% acrylamide resolving and 4% 
stacking) with a PageRuler Prestained Protein Ladder (Fermentas) in 1X SDS-PAGE 
running buffer  (25 mM Tris-base, 190 mM glycine and 0.1% (w/v) SDS).  All protein 
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gels were stained with Coomassie Brilliant Blue and destained with 10-20% (v/v) acetic 
acid.  
All UV-visible absorption spectra or measurements were obtained with a Varian 
UV-vis Cary100 Spectrophotometer with Temperature Controller (Walnut Creek, CA). 
High performance liquid chromatography was performed with an Agilent 1000 Series 
HPLC (Foster City, CA) equipped with 1100 Series multiple wavelength detector and 
1200 Series fluorescence detector. Electrospray ionization mass spectrometry with 
tandem mass spectrometry (ESI-MS/MS) was performed with an LTQ Orbitrap XL 
(Thermo Scientific; San José, CA) in the Proteomic Core Facility at the University of 
Maryland (College Park, MD). Metal analysis of Orf13 by inductively coupled plasma 
mass spectrometry (ICP-MS) was performed in Department of Geological Sciences at 
Michigan State University (East Lansing, MI). Anaerobic experiments were performed in 
an 830-ABC series compact glovebox (PLAS-LABS, Inc; Lansing, MI) equipped with a 
Model 10 Gas Analyzer and Digital Heated Fan Box with palladium catalyst bed (Coy 
Laboratory Products, Inc; Grass Lake, MI).  
Cloning of His6SUMO-Orf13 and native Orf13. The gene encoding Orf13 was 
amplified by PCR from the p-ANT-1 cosmid containing the anthramycin gene cluster that 
was constructed by Dr. Wei Li in our laboratory (unpublished results). NdeI and HindIII 
restriction sites (underlined) were incorporated into the primers for insertion into the 
pSMT3 and pET24a vectors; forward primer 5’-
GGTGGTCATATGAGCAACGGCCGAGG-3’ and reverse primer 5’-
GGTGGTAAGCTTTCATGACCGGGCTTCC-3’. Amplified orf13 was isolated by 
QIAquick gel extraction kit (Qiagen), digested with NdeI and HindIII, ligated into the 
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pSMT3 and pET24a vectors, and transformed into GeneHogs (Invitrogen; Carlsbad, CA). 
DNA sequencing confirmed correct construction of the pSMT3/orf13 and pET24a/orf13 
plasmids for the recombinant expression of His6SUMO-Orf13 and native Orf13, 
respectively, in BL21(DE3) E. coli.  
Expression of Orf13 constructs in BL21(DE3) E. coli. Individual constructs of 
Orf13 plasmids (pSMT3/orf13 or pET24a/orf13) (50-100 ng) were incubated with 40 µL 
of electro-competent BL21(DE3) E. coli cells for 2 min on ice, transformed by 
electroporation at 2500 V, transferred to 1 mL of LB medium and were allowed to 
recover for 1 hr at 37 °C. After recovery, 10-20 µL of cells were plated on LB agar 
containing kanamycin (50 µg/mL) and incubated for 10-12 hr at 37 °C. One colony per 
seed (starter) culture of LB medium (50 mL in 250 mL Erlenmeyer flask) with 50 µg/mL 
kanamycin antibiotic selectivity was selected and grown to oversaturation for 12-15 hr at 
37 °C at 250 rpm. An aliquot of the seed culture (20 mL) was used to inoculate an 
expression culture of LB medium (2 Liters in a 4 Liter Erlenmeyer flask) with 50 µg/mL 
kanamycin antibiotic selectivity and protein expression was induced with D-lactose (0.2% 
w/v) when the optical density of the cells at 600 nm (OD600) reached 0.8 – 1.0. Protein 
expression occurred for 8 hr at 37 °C with a rotation speed of 250 rpm. Cells were 
harvested 8 hr after induction by centrifugation at 5,000 rpm for 10 min at 4 °C. The cell 
pellets were flash frozen in liquid nitrogen and stored at -80 °C until purification. 
Optimized expression conditions for native Orf13 are as previously described with only 
the addition of ferric iron (III) citrate (500 µM final) in the expression culture. In the 
preparation of the expression culture, solid iron (III) citrate is added to the media and 
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autoclaved (Note: this iron salt form is only soluble when added to boiling solutions or 
media which is then autoclaved). 
Cloning and expression of native Orf13 for RP523 E. coli. The orf13 gene was 
also cloned into the pCW vector for recombinant expression in RP523 E. coli by 
digestion of pET24a/orf13 with HindIII and NdeI and insertion into the pCW vector cut 
with the same restriction enzymes. DNA sequencing confirmed the correct construction 
of pCW/orf13. This construct was transformed into RP523 E. coli cells as described for 
BL21(DE3) E. coli. However, all cells were grown in Terrific Broth (TB) media with 
ampicillin (75 µg/mL) antibiotic selectivity in the presence of hemin (30 µg/mL).    
Purification of His6SUMO-Orf13. One gram of cells expressing His6SUMO-
Orf13 was chemically lysed with 1X BugBuster
®
 (Novagen) and lysozyme (0.5 mg/mL) 
by mild inversion in buffer A (50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 25 mM 
ascorbate, 1 mM DTT and 1 mM PMSF) and centrifuged at 15,000 rpm for 30 min at 4 
°C. The cell free extract was loaded onto a 2 mL column of Ni-NTA (Qiagen) pre-
equilibrated with buffer A. The column was washed at 1 mL/min at 4 °C in the following 
sequence with buffer A: 20 column volumes (CV) of buffer A only, 10 CV with 20 mM 
imidazole, a 10 CV linear gradient from 20 to 50 mM imidazole, 10 CV with 50 mM 
imidazole, a 10 CV linear gradient from 50 to 100 mM imidazole, and 10 CV with 100 
mM imidazole. Fractions containing His6SUMO-Orf13, assessed by SDS-PAGE, eluted 
at 100 mM imidazole and were pooled and concentrated using a filtration chamber under 
nitrogen gas with an Amicon membrane (30 kDa MWCO; Millipore, Billerica, MA) to 
~1 mg/mL. Cleavage to remove the His6SUMO fusion tag was performed using the Ulp1 
Sumo protease at a mass ratio of 1:50 (Ulp1:His6SUMO-Orf13) for 12 hr during dialysis 
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against buffer A at 4 °C. The protein solution was then re-loaded onto the Ni-NTA 
column re-equilibrated with buffer A, but finally eluted with 200 mM imidazole (See 
Results and Discussion).    
Purification of native Orf13. Six grams of cells expressing native Orf13 were 
lysed by French press (4 passes at 10,000 psi) and the cell free extract was loaded onto a 
6 mL column of Ni-Sepharose pre-equilibrated with buffer A (50 mM sodium phosphate 
(pH 8.0), 300 mM NaCl and 1 mM DTT). The column was washed with 20 column 
volumes of buffer A containing 20 mM imidazole at 1 mL/min at 4 °C. Orf13 was eluted 
with 3 column volumes of buffer A containing 80 mM imidazole and fractions containing 
the enzyme were pooled and concentrated using a filtration membrane Amicon (30 kDa 
MWCO) by centrifugation (Millipore; Billerica, MA) to a concentration of 15-20 mg/mL. 
The concentrated enzyme solution was then loaded onto a S-200 HR column (2.5 x 40 
cm; 196 mL CV) pre-equilibrated with buffer B (10 mM imidazole, 50 mM sodium 
phosphate (pH 8.0), 300 mM NaCl and 10% glycerol) and eluted at 0.4 mL/min at 4 °C. 
Fractions containing Orf13 were pooled and concentrated to at least 10 mg/mL as 
previously described, flash frozen by liquid nitrogen in droplet form and stored at -80 °C. 
Purity of Orf13 was greater than 95% as judged by SDS-PAGE (Figure 2-2D). The 
protein concentration was determined using the experimentally determined extinction 




 (pH 8.0, 25 °C) with final purification yields of 2-
3 mg of Orf13 per gram of cell lysed.  
An alternative purification method for native Orf13 by anionic exchange 
chromatography was also developed. Six grams of cells were lysed by French press and 
the cell free extract was loaded onto a Q-Sepharose column (2.5 x 49 cm; 240 mL CV) 
20 
 
pre-equilibrated with buffer A (50 mM sodium phosphate (pH 8.0), 30 mM NaCl, 50 mM 
DTT and 10% glycerol). The column was washed with 3 CV of buffer A at 2 mL/min at 
4 °C, followed by a salt gradient of 30 mM – 600 mM NaCl within 1.2 Liters. Orf13 
eluted between 120 – 150 mM NaCl of the linear gradient and fractions containing the 
enzyme were pooled and concentrated to 10 mg/mL as previously described. Gel 
filtration S-200HR chromatography was performed as described before with buffer 
containing 50 mM sodium phosphate (pH 8.0), 300 mM NaCl, 50 mM DTT and 10% 
glycerol. Orf13 was obtained with similar yield and purity as with the Ni-Sepharose 
purification method.  
An optimized purification system was developed for native Orf13. This involved 
the final gel filtration step to be carried out in an anaerobic glove box to obtain stable 
Orf13 without the presence of imidazole. Cell lysis and the Ni-Sepharose purification 
steps for native Orf13 were performed as described above. The concentrated protein 
solution in an open conical tube (15 mL) was brought into an anaerobic glove box after 4 
cycles of high vacuum degassing (-70 kPa) and N2 (g) purge in the antechamber, and 
allowed to equilibrate in the anaerobic glove box for 10 minutes. The protein solution 
was loaded onto an anaerobic S-200 HR column (2.5 x 40 cm; 196 mL CV) pre-
equilibrated with anaerobic buffer C (20 mM sodium phosphate (pH 8.0), 80 mM NaCl 
and 10% glycerol) and eluted at 0.4 mL/min at 25 °C. Fractions containing Orf13 were 
pooled and concentrated to at least 10 mg/mL as previously described, but with the 
important exception that the centrifugation membrane filter used for concentration had 
been stored in the glove box 1 week prior to purification and was sealed with pressure 
sensitive tape (vinyl  plastic delineator tape; Fisher Scientific) prior to removal from the 
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glove box to maintain anaerobic conditions. The concentrated protein solution in the 
sealed centrifugation membrane filter was brought back into the glove box after 4 cycles 
of high vacuum degassing (-70 kPa) and N2 (g) purge in the antechamber, and the protein 
was flash frozen by liquid nitrogen in droplet form within the glove box. The frozen 
enzyme droplets were quickly transferred to a storage tube, removed from the glove box 
and stored at -80 °C. Anaerobic Orf13 was obtained with similar yield, purity and 
stability (Figure 2-2E) as the aerobic Ni-Sepharose and gel filtration purification method 
initially described.    
Quaternary structure determination by gel filtration. The oligomeric state of 
purified native Orf13 was determined using a Superdex200 column (1 x 30 cm; 24 mL 
CV) pre-equilibrated at 4 °C with 50 mM sodium phosphate (pH 8.0), 150 mM NaCl and 
50 mM DTT at 0.4 mL/min. Molecular weight standards used were ribonuclease A (13.7 
kDa), ovalbumin (44 kDa), conalbumin (75 kDa) and aldolase (158 kDa). 
High performance liquid chromatography and mass spectrometry for 
porphyrin detection and identification. An HPLC method to detect porphyrins was 
performed as previously described (39). Samples (110 µL) of Orf13 and/or standards of 
heme B (iron protoporphyrin IX) or protoporphyrin IX (PPIX) were incubated at room 
temperature for 1 hr in 2% (w/v) SDS. Porphyrins were detected at 405 nm. Heme B and 
PPIX standards had average retention times of 42 and 44 minutes, respectively. The 
peaks observed at 42 and 44 minutes from the Orf13 sample were collected, treated with 
formic acid (1%, v/v) and injected at 25 µL/min into an LTQ Orbitrap XL mass 
spectrometer. The parent ions of 616.3 m/z and 563.5 m/z observed for the 42 and 44 
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minute samples, respectively, were selected for fragmentation by Collision Induced 
Dissociation (CID). Heme B and PPIX standards were treated and analyzed accordingly.  
Heme B quantitation and stoichiometry. The pyridine hemochromagen method 
was performed as described (40) with a UV-vis Cary100 Spectrophotometer. A basic 
pyridine solution containing 50% (v/v) pyridine and 200 mM NaOH was prepared fresh 
for all analyses. The concentration of heme B from Orf13 samples is calculated with the 




 and the stoichiometric ratio of heme B determined 
by the molar ratio of heme B to Orf13. All analyses were performed in triplicate.  
Circular dichroism measurements of Orf13. Far-UV CD measurements were 
performed on a Jasco J-810 Spectropolarimeter (Easton, MD) at 25 °C using rectangular 
quartz cells with a path length of 1.0 mm. The protein concentration of Orf13 with 100% 
heme B occupancy was 4 µM in 20 mM sodium phosphate (pH 8.0). The spectra were 
recorded with a 1 nm wavelength step at a scanning speed of 50 nm/min. Each spectrum 
was averaged from three continuous scans and corrected by subtraction of a blank run 
containing 20 mM sodium phosphate (pH 8.0). 
2.3 Results and Discussion 
Purification and enzyme stability of Orf13. Cell pellets after over expression of 
Orf13 are red in color and the color of the expression media becomes dark brown or 
black when expression is continued for more than 8 hours. The red cell color was the first 
indication of a cofactor likely bound to Orf13, while production of the black pigment 
suggested the enzyme to be active since this has been observed for the oxidative 
polymerization of L-DOPA (41). The first pilot purification of Orf13 with His6SUMO-
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Orf13 (pSMT3/orf13) revealed an intrinsic binding affinity of the native, non-fusion 
tagged protein with the Ni-NTA resin. This was observed after treatment with the Ulp1 
protease had successfully cleaved the His6SUMO fusion tag from Orf13, but the non-
fusion tagged protein remained bound to the resin during the 2
nd
 Ni-NTA purification 
step when washed with buffer A (Figure 2-1).  
 
 
Figure 2-1. SDS-PAGE of His6SUMO-Orf13 purification. Lanes 1 and 11 – Fermentas 
pre-stained protein ladder; lane 2 – cell free extract of soluble His6SUMO-Orf13 (MW 
47.4 kDa); lane 3 – pooled His6SUMO-Orf13 after 1
st
 Ni-NTA step; lane 4 – pooled 
His6SUMO-Orf13 after the Ulp1 cleavage reaction; lanes 5-7 – 2
nd
 Ni-NTA fractions 
washed with buffer A; lanes 8-10 – fractions of non-fusion tagged Orf13 (MW 33.6 kDa) 
from 2
nd
 Ni-NTA washed with buffer A containing 200 mM imidazole.    
 
The strategy for performing the 2
nd
 Ni-NTA step after the Ulp1 cleavage reaction 
is to easily separate the native protein from the cleaved His6SUMO tag. The His6SUMO 
fusion tag will remain bound to the Ni-NTA resin re-equilibrated with buffer lacking 
imidazole while the native protein elutes from the column (38). This method has been 
successfully employed in our laboratory (42); however, this was not the case for Orf13. 
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The red colored protein eluted from the resin with 200 mM imidazole and SDS-PAGE of 
selected fractions during the first purification attempt had confirmed the removal of the 
His6SUMO fusion tag (Figure 2-1, lanes 4 and 8-10). 
The intrinsic binding affinity of Orf13 to the Ni-NTA resin was further explored 
with expression and purification of native, non-fusion tagged Orf13 (pET24a/orf13). 
Overall, native Orf13 binds more effectively to Ni-Sepharose (G.E. Healthcare) than Ni-
NTA (Qiagen) resin, is retained on the resin bed with buffers containing 20 mM 
imidazole and completely elutes with 80 mM imidazole. This allowed for optimization of 
the Ni-Sepharose purification step (See General Methods) which consistently results in 
highly pure Orf13 (Figure 2-2A-E, lane 4). A final gel filtration step was added to the 
purification process to ensure homogeneity of the purified protein sample for all future 
studies, including assessment of cofactor stoichiometry, protein crystallization and 
steady-state kinetic analysis of Orf13. However, gel filtration of Orf13 proved to be a 
significant challenge as protein instability and degradation occurs readily (Figure 2-2A, 
lane 5). Protease activity as the source of the protein degradation was ruled out when 
similar degradation patterns were observed after performing gel filtration in the presence 
of a protease inhibitor cocktail (Sigma) (result not shown; refer to Figure 2-2A, lane 5).  
The consistent protein degradation pattern of Orf13 following gel filtration always 
included degradation below the monomeric band (33.6 kDa) and the appearance of a MW 
band corresponding to a covalent dimer (~68 kDa) in denaturing SDS-PAGE gels. It was 
hypothesized that the protein instability and degradation is auto-oxidative in nature, 
relating to its oxygen sensitivity that is most likely promoted by some type of bound 




Figure 2-2. SDS-PAGE gels of native Orf13 purification without oxidative protection 
(A), with oxidative protection in the presence of 50 mM ascorbate (B), 50 mM DTT (C), 
10 mM imidazole (D), or in a glove box under anaerobic conditions (E) during gel 
filtration. Lane 1 – un-induced pET24a/orf13 in BL21(DE3) E. coli; lane 2 – induced 
native Orf13 (MW 33.6 kDa); lane 3 – cell free extract; lane 4 – Pooled Orf13 after Ni-
Sepharose step; and lane 5 – Pooled Orf13 after S-200 HR gel filtration. 
 
Various gel filtration buffer conditions were assessed to obtain stable and active 
Orf13. Overall, the auto-oxidative damage of the protein is preventable when gel 
filtration is performed in the presence of reducing agents, such as ascorbate (50 mM) 
(Figure 2-2B) or DTT (50 mM) (Figure 2-2C), in the presence of imidazole (10 mM) 
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(Figure 2-2D), or under anaerobic conditions in a glove box without any chemical 
protectant (Figure 2-2E). Protein stabilization observed in the presence of reducing agents 
or in the absence of oxygen supported the proposed auto-oxidative degradation behavior. 
With the ability to successfully protect Orf13 from oxidative damage, the quaternary 
structure in solution was determined by gel filtration. Orf13 exists as a monomer in 
solution with an experimentally observed molecular weight of 37.9 kDa consistent with 
the predicted monomeric weight of 33.6 kDa (See Appendix A-1). Additionally, the 
experimental monomeric mass of Orf13 by MALDI-TOF-MS has an average 
monoisotopic peak of m/z 33,676 ± 58 Da that is also similar to the predicted value (See 
Appendix A-2). 
Identification of heme B bound to Orf13. The visible red color of Orf13 
indicated a bound cofactor. Characteristic absorbance bands of a heme moiety were 
observed in a UV-visible absorption spectrum of purified Orf13 (Figure 2-3). The Soret 
band at 408 nm indicated a ferric heme-iron in a penta-coordinate state based on the 
presence of a Q-band at 630 nm. The position of the Soret band in Orf13 is generally 
observed between 403-405 nm when purified anaerobically, 407 – 410 nm in the 
presence of ascorbate or imidazole, and 420-425 nm in the presence of DTT. Heme B 
was identified as the heme moiety non-covalently bound to Orf13 by co-elution with 





Figure 2-3. UV-visible absorption spectrum of purified Orf13 (100% heme B occupancy) 
in 20 mM Tris-HCl (pH 8.0), 10 mM imidazole and 10% glycerol. Soret band of heme B 
is observed at 408 nm and Q-bands at 530 nm, 561 nm and 630 nm (inset). Figure was 
modified from Connor, KL et al (43). 
 
 
Figure 2-4. HPLC chromatograms for porphyrin detection: (A) Supernatant of denatured 
Orf13 sample; (B) Co-injection of the sample shown in A with heme B standard. Figure 
was modified from Connor, KL et al (43). 
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The HPLC peak at 42 minutes from the supernatant of denatured Orf13 was 
confirmed as heme B with subsequent ESI-MS/MS analysis (Figure 2-5). The precursor 
ion of 616.3 m/z is the same m/z observed in the heme B standard sample collected by 
HPLC at 42 minutes. It appears at exactly its molecular weight due to a radical porphyrin 
cation (44). ESI-MS/MS fragmentation of the precursor ion (616.3 m/z) generated a 
product ion peak at 557.2 m/z. The 59 amu difference in the product ion corresponded to 
the loss of –CH2COOH from one of the propanoic acid groups of heme B (45). This same 




Figure 2-5. (A) ESI-MS of peak (TR 42 min, Figure 2-4A) collected from HPLC of the 
supernatant from denatured Orf13; (B) ESI-MS/MS fragmentation of the precursor ion at 
616.3 m/z generated a product ion peak at 557.2 m/z. Figure was modified from Connor, 
KL et al (43). 
 
The stoichiometry of heme B in Orf13.  Quantitation of heme B in Orf13 using 
the pyridine hemochromagen method (See Appendix A-3) showed a wide range of 
occupancy from 10% to 100% with Orf13 purified under conditions protecting the 
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enzyme from degradation.  Orf13 with 100% heme B occupancy has a Reinheitszahl 
(RZ) value of 1.8, which is defined as the ratio of the Soret band absorbance (selected at 
408 nm for Orf13) to the protein absorbance at 280 nm (Note: 100% heme B occupancy 
is defined as 1 heme B moiety per monomer of enzyme). Indications of second porphyrin 
species bound to Orf13 were first evident when the enzyme was purified in the presence 
of DTT and sub-stoichiometric amounts of heme B were measured. Two different Soret 
band species at 409 nm and 420 nm were commonly observed (Figure 2-6), where the 
latter species at 420 nm is heme B in a ferrous heme-iron state due to the presence of 
DTT.  Auto-oxidation of ferrous heme-iron to ferric heme-iron was observed by a shift in 
the Soret band position from 420 nm to 404 nm, respectively, after buffer exchange to 
remove DTT and substitute with imidazole to protect Orf13 from degradation. The 
presence of the second porphyrin species had been initially masked by the Soret band of 
heme B in the ferric oxidation state.   
 
 
Figure 2-6. UV-visible absorption spectrum of Orf13 containing 75% heme B and 25% 
protoporphyrin IX (PPIX) before (solid line) and after (dashed line) buffer exchange to 
remove DTT (50 mM) and replace with imidazole (10 mM) in the storage buffer. Figure 
was modified from Connor, KL et al (43).  
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The Soret band species at 409 nm (Figure 2-6) was identified as protoporphyrin 
IX (PPIX), which remained unaffected by reducing agents as it lacks an iron center. The 
presence of PPIX bound to Orf13 was confirmed by co-injection of PPIX with Orf13 that 
showed an increase in the peak height of the compound observed at 44 minutes by HPLC 
(Refer to Figure 2-4; See Appendix A-4), and ESI-MS/MS analysis (See Appendix A-5). 
The amount of PPIX bound to Orf13 was determined by a calibration curve using HPLC 




 in 2.7 M HCl (46)) 
from which the stoichiometry was calculated by the molar ratio of PPIX and Orf13. 
Overall, the amount of PPIX bound to Orf13 made up the occupancy difference when 
sub-stoichiometric amounts of heme B were measured in purified enzyme (i.e. 75% heme 
B and 25% PPIX). No other organic cofactors were identified with Orf13 and no other 
metals, other than iron originating from heme B, were found by ICP-MS. 
This is the first reported case in which a heme containing enzyme has been found 
to be fully occupied with a heterogeneous mixture of heme B and PPIX. Dissociation 
constants of heme B for enzymes utilizing the heme moiety in different capacities show a 
range of heme binding affinities; myoglobin for oxygen transport (1.3 x 10
-14
 M) (47), 
bovine serum albumin for transport (4.6 x 10
-9
 M) (48), pa-HO, a heme oxygenase, for 
heme degradation (0.6 x 10
-6
 M) and PhuS involved in heme binding, trafficking and 
transfer (0.2 x 10
-6
 M) (49). The dissociation constant of PPIX for ferrochelatase (1.5 x 
10
-6
 M) (50) is similar to the heme B binding affinity for pa-HO and PhuS. Heme B and 
PPIX are tightly bound to Orf13 as there is no exchange or loss during dialysis unless the 
enzyme is denatured with 6 M guanidinium hydrochloride or 2% SDS to remove either 
species. The occupancy ranges of heme B and PPIX with Orf13 may indicate this enzyme 
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to have similar binding affinities for both porphyrin moieties. The lack of in vivo binding 
discrimination between heme B and PPIX may also suggest stronger binding interactions 
with protein residues and substituents of porphyrin ring (i.e. the propanoic acid or vinyl 
groups) than the axial residue(s) coordinating the heme-iron.  
The extensive variability in heme B occupancy for Orf13 was observed in 
expression batches from the same seed culture, prepared in the same liquid media, and 
grown and expressed on the same shaker using identical flasks. Heme dependent 
enzymes obtained from E. coli expression systems that require a non-covalently bound 
heme exist largely in an apo-form with partial heme occupancy and without the presence 
of PPIX (51-53). Complete heme occupancy can be readily achieved by addition of heme 
to the enzyme by titration without the need for protein denaturation and refolding. In 
vitro titration of heme B to purified Orf13 did not exchange the bound PPIX and the 
enzyme remained fully occupied with a heterogeneous mixture of both porphyrin species. 
Attempts to obtain an apo-form of Orf13 for in vitro heme titration was also unsuccessful 
since the enzyme failed to express when 1,10-phenanthroline, a metal chelating agent, 
was added to the growth medium. In an effort to increase and control the in vivo 
incorporation of heme B in Orf13, δ-aminolevulinic acid (δ-ALA, a heme biosynthetic 
precursor (54)), exogenous non-heme iron (such as iron (II) sulfate (FeSO4) or 
ammonium iron (II) sulfate, Mohr’s salt (NH4)2Fe(SO4)2●6H2O)) with or without δ-ALA, 
or exogenous hemin were added to the medium for expression in BL21(DE3) E. coli. 
This strategy was ineffective as similar results in heme B occupancy (30-100%) were 
observed compared to Orf13 expression without any additives. It was also determined 
that the range in heme B and PPIX occupancies with Orf13 is independent of the 
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purification method. Purification of Orf13 by anionic exchange (Q-Sepharose) in the 
presence of excess DTT (50 mM) to protect Orf13 from auto-oxidative degradation 
showed the same variable heme B occupancies as the metal affinity method (Ni-
Sepharose). This confirmed that heme B bound to Orf13 was not compromised, lost or 
competed out due to the enzyme’s ability to intrinsically bind to the Ni-Sepharose resin.  
An alternative E. coli expression system for in vivo incorporation of heme B in 
Orf13 was also tried using RP523 E. coli with exogenous hemin.  RP523 is a porphyrin 
permeable strain of E. coli with a mutation in the hemB gene of the heme biosynthetic 
pathway that disrupts the normal biosynthesis of heme B. Therefore, RP523 cells are 
dependent on the uptake of exogenous heme B for survival (55). This expression system 
has been established for substituting nitric oxide synthase (NOX), a heme dependent 
enzyme, with different metalloporphyrins (39, 56). The advantage in utilizing this system 
for Orf13 expression is that these cells lack the ability to synthesize porphyrin and are 
only viable in the presence of heme B, thus eliminating the presence of PPIX with Orf13. 
RP523 E. coli cells expressing Orf13 using the pCW/orf13 construct were red in color as 
observed with Orf13 expression in BL21(DE3) E. coli. However, it was difficult to obtain 
stable Orf13 using the developed purification methods previously described. Severe 
degradation of Orf13 was evident after the Ni-Sepharose method in the presence of 
imidazole. Orf13 eluted as a brownish-yellow enzyme and showed auto-oxidative 
degradation by SDS-PAGE with a predominant protein band at double the monomeric 
weight of Orf13 that was commonly observed in purifications of Orf13 from BL21(DE3) 
E. coli without oxidative protection (Refer to Figure 2-2A, lane 5). Repeating the Ni-
Sepharose purification under anaerobic conditions in a glove box prevented dimerization 
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of Orf13 and the enzyme retained its red color. The visible absorption spectrum of heme 
B bound to Orf13 was similar to Orf13 purified from BL21(DE3) E. coli (Refer to Figure 
2-3). However, the overall yield and purity were very poor. Purification by the Q-
Sepharose method with excess DTT (50 mM) prevented covalent dimerization and 
improved the purity of the protein sample. However, Orf13 eluted as a bright yellow 
enzyme with an unusual visible absorption spectrum of the heme displaying a broad Soret 
band at 420 nm without distinguishable Q-bands. In addition, the heme species bound to 
Orf13 could not be reduced by dithionite to assess its heme B stoichiometry by the 
pyridine hemochromagen method. Overall, the feasibility of obtaining sufficient amounts 
of highly pure and stable Orf13 fully occupied with heme B from RP523 E. coli was 
unsuccessful and proved more challenging than the purification of Orf13 expressed in 
BL21(DE3) E. coli.       
Full heme B incorporation into native Orf13 was finally achieved with 
BL21(DE3) E. coli expression of the protein in the presence of ferric iron (III) citrate.  
Use of this iron chelate as an additive during expression consistently results in Orf13 with 
an average heme B occupancy of 102 ± 11%. This is a outstanding result compared to the 
previous attempts with other exogenous non-heme iron additives which had produced 
variable heme B occupancies (30-100%). The success of ferric iron (III) citrate over other 
iron chelate forms is directly related to the iron metabolism of E. coli. There is an 
intrinsic ferric iron citrate transport mechanism in E. coli that is one of several pathways 
for exogenous iron uptake essential for iron metabolism (57). Iron (III) citrate acts as its 
own signaling molecule and is taken up by the bacteria, increasing the effective 
concentration of iron in the cell that can be utilized by other metabolic pathways. Thus, it 
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is plausible that more iron is available for the final step of heme biosynthesis when 
ferrochelatase inserts an iron atom into PPIX to produce heme B. The resulting outcome 
is the complete occupation of native Orf13 with heme B. The BL21(DE3) E. coli cells 
transformed with pET24a/orf13 are grown in the presence of iron (III) citrate in the 
expression media; after inoculation from the seed culture and all the way through until 
the cells are harvested after induction with D-lactose. All other expression conditions and 
observations, including the average cell growth rate, remain the same as previously 
described. Moreover, expression of native Orf13 in the presence of iron (III) citrate 
allows full in vivo incorporation of heme B. The predominant secondary structure 
conformation of Orf13 with 100% heme B is alpha-helical with an absorbance maximum 
at +190 nm and minima at -210 nm and -222 nm (Figure 2-7). This is common among 
heme containing proteins (58, 59).   
 
 
Figure 2-7. Far-UV circular dichroism spectrum of Orf13 (100% heme B) in 20 mM 










The identification of heme B with purified native Orf13 suggests that this enzyme 
may be a heme dependent tyrosine hydroxylase. No other organic cofactors were 
identified with Orf13 and no other metals, other than iron originating from heme B, had 
been found by ICP-MS. This information excludes classification of Orf13 as any of the 
non-heme dependent MMOs, in particular, the non-heme iron pterin or α-KG dependent 
enzymes and the copper dependent tyrosinases that catalyze the ortho-hydroxylation of L-
tyrosine to L-DOPA (33, 34). The heme dependent MMO class includes two types of 
enzymes; the cytochrome P450 enzymes and heme peroxidases. To assess the catalytic 
requirement of heme B for Orf13 as a putative tyrosine hydroxylase, the reaction 
requirements and catalytic cycles of cytochrome P450s and heme peroxidases were 
considered.   
Cytochrome P450 enzymes catalyze aromatic hydroxylation by the transfer and 
insertion of an oxygen atom into an aromatic substrate, where the oxygen source is 
dioxygen (O2; molecular oxygen) (Figure 3-1) (29, 59). Binding and activation of 
dioxygen during the catalytic cycle only occurs after an aromatic substrate binds to the 
enzyme in the ferric resting state and the ferric heme-iron is reduced by 1-electron to the 
ferrous state. This first electron originates from NAD(P)H that is supplied through a 
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flavin ferredoxin domain or by a FMN reductase (60, 61). The ferrous-dioxygen complex 
can accept a second electron from NAD(P)H through an electron transfer system to 
produce a ferric peroxy-anion species which is protonated to form Compound 0, the ferric 
hydroperoxy complex. Heterolytic cleavage between the oxygen atoms generates 
Compound I, a radical oxo-ferryl intermediate, which then inserts the oxygen atom into 
the aromatic substrate by a proposed oxygen rebound mechanism (62-64). This returns 
the heme-iron to the ferric resting state and the hydroxylated product dissociates to 
complete the catalytic cycle.   
 
 
Figure 3-1. The consensus mechanism of aromatic hydroxylation for cytochrome P450 
catalysis; (1) native ferric enzyme resting state occupied with water, (2) ferric heme-
substrate complex, (3) ferrous heme-substrate complex, (4) ferrous-dioxygen complex, 
(5) ferric peroxy-anion complex, (6) ferric hydroperoxy complex (Compound 0), (7) oxo-
ferryl radical complex (Compound I), (8) product-ferric complex.   
 
The main catalytic function of heme peroxidases is the oxidation of aromatic 
substrates by 2-sequential 1-electron transfer reactions with hydrogen peroxide (Figure 3-
2) (29, 31, 65). In the catalytic cycle, hydrogen peroxide is used directly to generate 
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Compound 0 from the ferric resting state. It is not obligatory for an aromatic substrate to 
bind prior to hydrogen peroxide in order to generate this intermediate. Heterolytic 
cleavage of the O-O bond generates Compound I, a radical oxo-ferryl intermediate, 
which can complete the first 1-electron transfer reaction to an aromatic substrate to 
generate a radical product. Compound I is converted to Compound II, an oxo-ferryl 
intermediate, which can react with a second aromatic substrate to generate another radical 
product to complete the second 1-electron transfer reaction and return the enzyme to the 
ferric resting state. Overall, one reaction cycle produces two 1-electron oxidized aromatic 
products without the transfer of oxygen, and hydrogen peroxide is converted into 2 water 
molecules. While both heme peroxidases and cytochrome P450s are classified as 
oxidoreductases (EC 1.x.x.x) (66) and show similarities in their catalytic cycles, heme 
peroxidases do not catalyze aromatic hydroxylation with hydrogen peroxide. 
 
 
Figure 3-2. The catalytic cycle of heme peroxidase for the oxidation of phenol; (1) native 
ferric enzyme resting state occupied with water, (2) ferric hydroperoxy complex 
(Compound 0), (3) oxo-ferryl radical complex (Compound I), (4) oxo-ferryl complex 
(Compound II). 
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Another important feature that generally distinguishes cytochrome P450s and 
heme peroxidases is the residue that coordinates the heme-iron in the axial position. This 
residue is known as the proximal or 5
th
 ligand and is highly conserved. The proximal (5
th
) 
ligand in cytochrome P450s is a cysteine (most common) or methionine residue, where 
the heme-iron coordination is referred to as thiolate-ligated (29, 59). Classical heme 
peroxidases are histidyl-ligated where a histidine residue acts as the proximal (5
th
) ligand 
(29, 31, 65, 67).  
Knowledge of the reaction requirements and catalytic cycles of cytochrome P450s 
and heme peroxidases provided the initial conditions in which to assess the catalytic 
requirement of heme B in Orf13. The key sequence of objectives in the functional 
characterization of Orf13 was 1) to determine whether the enzyme is active and catalyzes 
L-tyrosine hydroxylation, 2) to determine the reaction conditions needed for catalysis, 
and 3) assign the classification of the enzyme based on the reaction requirements.  
3.2 Experimental Procedures 
Materials. Sodium phosphate, imidazole, sodium dithionite, and hydrogen 
peroxide (30% solution) were purchased with the highest purity from ThermoFisher 
Scientific (Fair Lawn, NJ). Dithiothreitol (DTT) was purchased from American 
Bioanalytical Inc. (Natick, MA). Catalase, superoxide dismutase (SOD) and all other 
chemicals were purchased with the highest purity from Sigma Aldrich (St. Louis, MO). 
Carbon monoxide gas, CO (g), was kindly provided by the laboratory of Professor 
Eichhorn (University of Maryland, College Park, MD). 
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General Methods. All UV-visible absorption spectra or measurement of 
catechol-nitrite complexes for kinetic assays were obtained with a Varian UV-vis 
Cary100 Spectrophotometer with Temperature Controller (Walnut Creek, CA). High 
performance liquid chromatography was performed with an Agilent 1000 Series HPLC 
(Foster City, CA) equipped with an 1100 Series multiple wavelength detector and 1200 
Series fluorescence detector. Anaerobic experiments were performed in an 830-ABC 
series compact glovebox (PLAS-LABS, Inc; Lansing, MI) equipped with a Model 10 Gas 
Analyzer and Digital Heated Fan Box with palladium catalyst bed (Coy Laboratory 
Products, Inc; Grass Lake, MI).  
 Orf13 activity assays by HPLC-FLD for the detection of L-tyrosine and L-
DOPA. For assays assessing molecular oxygen dependent tyrosine hydroxylation, Orf13 
(2.5 µM) was pre-incubated in 50 mM sodium phosphate (pH 8.0) containing 15 mM 
DTT or 15 mM dithionite for 5 min on ice and then incubated for 5 min at 37 °C before 
addition of L-tyrosine (1 mM final) to start the reaction. In assays testing the requirement 
of hydrogen peroxide, Orf13 was pre-incubated with L-tyrosine (1 mM final) for 5 min 
on ice, 5 min at 37 °C and then hydrogen peroxide (0.1 mM final) was added to initiate 
the reaction. All assays were performed at 37 °C up to 15 min in triplicate. Four time 
point aliquots (75 µL) were quenched with 2.5 M HCl (10 µL) and chloroform (40 µL) 
was added to the quenched samples, spun at 3,400 rpm for 2 min at room temperature. 
The aqueous layer (65 µL) was transferred to new tube containing 2.5 M NaOH (10 µL). 
Each sample (20 µL) was analyzed by HPLC-FLD as described for the detection of L-
tyrosine and L-DOPA (68). L-Tyrosine and L-DOPA stocks were quantified 











respectively. L-DOPA and L-tyrosine standards had average retention times of 4.5 and 5.5 
minutes, respectively. The amount of L-DOPA produced by Orf13 was determined based 
on a calibration curve of L-DOPA made with standard samples quantified 
spectrophotometrically and treated under the same sample work up condition described. 
In Orf13 specific activity assays for the dihydroxyfumaric acid (DHFA) or L-ascorbate 
dependent reactions, Orf13 (2.5 µM) was pre-incubated with DHFA (2 mM) or L-
ascorbate (25 mM) for 5 min on ice and then 5 min at 37 °C in 100 mM sodium 
phosphate (pH 8.0). The reaction was initiated by addition of L-tyrosine (5 mM) and 
carried out for 15 min with time point aliquots quenched, prepared and analyzed as 
described above. These assays were performed in triplicate with or without catalase (75 
µg/mL) or superoxide dismutase (SOD) (100 µg/ml), or were performed in an anaerobic 





 (71).  
Steady-state kinetics of L-tyrosine hydroxylation by Orf13. A discontinuous 
assay was developed to monitor formation of L-DOPA in the hydrogen peroxide 
dependent reaction of Orf13 using a colorimetric method previously described (72, 73). 
Orf13 (0.3 – 1 µM; 75% heme B occupancy) was incubated with L-tyrosine for 5 minutes 
at 37 °C in 100 mM sodium phosphate (pH 8.0), followed by addition of hydrogen 
peroxide to initiate the reaction. Assays were performed in triplicate at 37 °C for 4 min 
with time points taken at 1, 2, 3, and 4 min in 90 µL aliquots quenched with 2.5 M HCl 
(10 µL). A solution containing 12.5% (w/v) sodium nitrite and 12.5% (w/v) sodium 
molybdate (35 µL) was added to the quenched samples and incubated for 10 min at room 
temperature. NaOH (10 µL, 3 M) was added to the sample and the L-DOPA-nitrite 
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complex was measured at 500 nm within 10-15 seconds. A standard curve of L-DOPA 
from 1 to 100 µM was prepared the same day for each set of assays. L-tyrosine and L-
DOPA stocks were quantified as previously described (69, 70). Hydrogen peroxide 




(71). Fixed variable concentrations of L-tyrosine (125 µM to 5 mM) at a fixed 
concentration of hydrogen peroxide (500 µM) were used to determine the steady-state 
kinetic parameters for L-tyrosine. Fixed variable concentrations of hydrogen peroxide 
(100 µM to 1 mM) at a fixed concentration of L-tyrosine (2 mM) were used to determine 
the steady-state kinetic parameters for hydrogen peroxide. The steady-state data for both 
L-tyrosine and hydrogen peroxide were fit to the Michaelis-Menten equation (Equation 3-
1) using the software program Prism 4 (GraphPad) to obtain the steady-state rate 
constants; vo/[Et] is the initial velocity of an enzyme normalized by the total enzyme 
concentration, [Et], in the steady-state assays, kcat is the maximal velocity macroscopic 
and catalytic rate constant, [S] is the concentration of the fixed varied substrate, and Km is 
the Michaelis-Menten constant which represents the concentration of the fixed varied 
substrate required to reach half-maximal velocity.  
Equation 3-1. 
vo/[Et] = kcat[S]/Km + [S] 
  Assay controls with a blank solution without Orf13 were used to correct for 
background. Orf13 background control assays were carried out with the same 
concentration of enzyme in the absence of substrates. No enzyme background at 500 nm 
was observed with 1.5 µM Orf13 or less. All controls were run in triplicate and in parallel 
with assay samples, and underwent the same colorimetric workup described above. For 
42 
 
all described specific activity and steady-state kinetic data, Orf13 was purified and stored 
in buffer B (10 mM imidazole, 50 mM sodium phosphate (pH 8.0), 300 mM NaCl and 
10% glycerol) to maintain stable enzyme with a ferric heme-iron oxidation state. Orf13 
purified and stored in the presence of 50 mM DTT was buffer exchanged into buffer B at 
4 °C using a G-50 column (1 x 5 cm; 4 mL CV) to remove DTT prior to enzyme assays. 
Auto-oxidation of the heme-iron to the ferric state upon buffer exchange was observed by 
a shift of the Soret band from 420 nm to 405 nm (Refer to Figure 2-6). 
Reduced-CO (g) spectrum of Orf13. A visible spectrum of Orf13 (4 µM) with 
100% heme B occupancy in 20 mM Tris-HCl (pH 8.0), 10 mM imidazole and 10% 
glycerol was initially measured to obtain a spectrum of the enzyme in the ferric resting 
state. Sodium dithionite (1-3 grains) was directly added to the sample; the quartz cuvette 
was sealed immediately with a small rubber stopper and then gently mixed. In a chemical 
fume hood, a syringe attached to a balloon filled with carbon monoxide gas (CO (g)) and 
a syringe to vent the sample were attached to the sealed cuvette. The sample was purged 
with CO (g) for 3 min and then a visible spectrum was measured to obtain the reduced-
CO (g) spectrum of Orf13. Note: a visible spectrum of the reduced sample after addition 
of dithionite was measured for comparison with the reduced-CO (g) spectrum to ensure 
sufficient CO (g) was present and bound to the reduced heme-iron. 
X-band Electron Paramagnetic Resonance (EPR) of ferric Orf13. Orf13 with 
50% heme B occupancy purified and stored in the presence of 50 mM DTT was buffer 
exchanged into 20 mM sodium phosphate (pH 8.0) at 4 °C using a G-50 column (1 x 5 
cm; 4 mL CV).  Auto-oxidation of heme B to the ferric state was observed after removal 
of DTT; however, ferricyanide (5 mM) was also added to Orf13 to ensure complete 
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oxidization of the heme-iron to the ferric state.  The ferricyanide was removed from the 
sample by a second G-50 column (1 x 5 cm; 4 mL CV) pre-equilibrated with 20 mM 
sodium phosphate (pH 8.0) at 4 °C. The final Orf13 sample was concentrated to 6 
mg/mL, diluted 1:1 (v/v) in 100% glycerol (300 µL final volume), transferred to an EPR 
quartz tube (250 mm length, 0.5 mm thickness, 4 mm O.D., Wilmad Lab Glass; 
Vineland, NJ) and flash frozen slowly in liquid nitrogen. This sample was stored at -80 
°C until EPR analysis. The EPR spectrum of Orf13 was obtained in the Department of 
Chemistry at Johns Hopkins University using a Bruker EMX EPR spectrometer 
controlled with a Bruker ER 041 X G microwave bridge at 15 K. The instrument was 
equipped with a continuous-flow liquid helium cryostat (ESR900) coupled to a 
temperature controller (TC503) made by Oxford Instruments, Inc. 
3.3 Results and Discussion 
Catalytic assessment of heme B in Orf13 for L-tyrosine hydroxylation. Orf13 
was not expected to be a heme dependent cytochrome P450-like enzyme since there are 
no conserved cysteine or methionine residues found in the multiple sequence alignment 
with its homologues (Figure 1-6). This was confirmed when DTT or dithionite reduced 
Orf13 in the presence of L-tyrosine did not produce L-DOPA. The production of L-DOPA 
was observed by HPLC-FLD when hydrogen peroxide was added to Orf13 in the 
presence of L-tyrosine (See Appendix A-6). This implicated the catalytic requirement of 
heme B. The HPLC-FLD assay method provided initial clues for catalytic activity, but 
was not used to further evaluate the hydrogen peroxide dependent reaction due to the 
limited sensitivity of the HPLC-FLD analysis. A modified discontinuous assay for 
spectrophotometric detection of L-DOPA in a DOPA-nitrite colorimetric complex (72, 
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73) was utilized to measure the specific activity and steady-state kinetics of Orf13. As 
part of the assay optimization process to observe turnover, the substrate order was 
evaluated under 3 different pre-incubation and reaction initiation conditions (Figure 3-3). 
Two important observations were made from this pre-incubation study: 1) maximal 
turnover occurs when Orf13 is pre-incubated with L-tyrosine followed with reaction 
initiation by addition of hydrogen peroxide, and 2) product formation begins to plateau 
after 3 minutes during the time course under the initial conditions tested.   
 
 
Figure 3-3. Progress curves of the L-tyrosine hydroxylation reaction by Orf13 under 
different substrate pre-incubation conditions. Assay conditions: 0.5 µM Orf13, 1 mM L-
tyrosine, and 400 µM H2O2 in 100 mM sodium phosphate (pH 8.0) at 37 °C. Orf13 (75% 
heme B) was pre-incubated 5 min at 37 °C with L-tyrosine (●), hydrogen peroxide (♦) or 
alone (▼). Reactions were initiated by addition of the substrate(s) not included during 
pre-incubation. L-DOPA formation was measured by the L-DOPA colorimetric assay. 
Data interpolation is shown beyond the time range for initial rate measurements. Figure 
was modified from Connor, KL et al (43). 
 
The optimized enzyme assay conditions to measure the specific activity of Orf13 
for the production of L-DOPA include 5 mM L-tyrosine, 500 µM H2O2 in 100 mM 
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sodium phosphate (pH 8.0) with a 4 min time course at 37 °C (See Methods). The 
specific activity of Orf13 correlated with the stoichiometry of heme B where maximal 
turnover of ferric-heme Orf13 (100% heme B) is 32 ± 2 min
-1
 compared to 21 ± 1 min
-1
 
with ferric-heme Orf13 (48% heme B). The specific activity is also dependent on the 
heme-iron oxidation state where ferric-heme Orf13 (48% heme B) had greater catalytic 
activity (21 ± 1 min
-1
) than Orf13 with ferrous-heme in the presence of 50 mM DTT (9 ± 
1 min
-1
). These data are in agreement with a catalytic starting state of ferric heme-iron for 
heme peroxidases (31) (Figure 3-2). Moreover, these results establish heme B as the 
cofactor required for catalysis and classify Orf13 as a heme dependent peroxidase 
catalyzing the ortho-hydroxylation of L-tyrosine to L-DOPA. 
Steady-state kinetics of Orf13.  The steady-state kinetic parameters for L-
tyrosine and hydrogen peroxide were determined using the L-DOPA colorimetric assay 
and the pre-incubation condition of Orf13 with L-tyrosine prior to reaction initiation by 
addition of hydrogen peroxide (Table 3-1; See Appendix A-7 and A-8 for Michaelis-
Menten analysis). The steady-state rate constants for hydrogen peroxide were also 
determined at two other fixed concentrations of L-tyrosine (5 mM and 0.45 mM) since 
saturation of hydrogen peroxide could not be achieved within the limits of the 
colorimetric assay (See Appendix A-9). Hydrogen peroxide at concentrations greater than 
1 mM affects the stability and reactivity of the molybdenum-nitrite colorimetric solution 
and also degrades L-DOPA, the product detected in the assay. The Michaelis-Menten 
analysis for the steady-state rate constants of hydrogen peroxide at the fixed 
concentrations of L-tyrosine listed above were within error of the original steady-state 
analysis at 2 mM L-tyrosine, which is reported in Table 3-1.  
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L-Tyrosine H2O2 0.45 ± 0.04 0.576 ± 0.005 (1.2 ± 0.1) x 10
3
 




Assays were performed at 37 °C with 0.3 – 1 µM Orf13 (75% heme B occupancy) 
in 100 mM sodium phosphate (pH 8.0). L-DOPA formation was measured using the 
L-DOPA colorimetric assay. Data are not normalized to heme B occupancy. 
b
These values are apparent Km constants at a partially saturating concentration of 
hydrogen peroxide (500 µM) and saturating concentrations of L-tyrosine (2 mM).  
 
 
The steady-state kinetic parameters for L-tyrosine hydroxylation by Orf13 fit to 
the Michaelis-Menten model are within the range of values reported for other heme 
peroxidases (74) and the catalytic efficiency for both substrates is similar. While 
comparison of the steady-state rate constants can be made to some extent based on use of 
a common cofactor (heme B) and requirement of hydrogen peroxide for catalysis, the 
overall products of these reactions are different. Orf13 hydroxylates L-tyrosine to L-
DOPA whereas classical heme peroxidases perform 2-sequential 1-electron oxidizations 
of aromatic substrates. Orf13 is the first heme peroxidase known to perform hydrogen 
peroxide dependent aromatic hydroxylation (43), and has the potential to establish a 
different mechanism. 
Reaction dependent behavior of Orf13 for L-tyrosine hydroxylation. Tyrosine 
hydroxylation to L-DOPA by Orf13 is also observed in the presence of L-ascorbate or 
dihydroxyfumaric acid (DHFA) (See Appendix A-10). The ascorbate and DHFA 
dependent reactions require molecular oxygen and have similar kobs that are 48 and 58 
fold less than the kobs of the hydrogen peroxide dependent reaction, respectively (Table 3-
2). Aromatic hydroxylation by the DHFA dependent reaction was abolished in the 
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presence of SOD, a superoxide scavenging enzyme, and was not observed with catalase. 
The ascorbate dependent reaction was not affected by SOD and decreased 4 fold in the 
presence of catalase. Interestingly, hydroxylation of phenols has been reported for 
horseradish peroxidase (HRP) in the presence of DHFA as an oxygen transfer reaction 
similar to cytochrome P450 enzymes (36, 37). The peroxygenase activity of HRP is 
promoted by non-enzymatic production of superoxide by DHFA and molecular oxygen, 
which then causes the formation of Compound III, an oxyferrous heme-iron state, when 
superoxide binds to the heme. Hydroxylation of phenol only occurs when substrate and 
additional reducing equivalents of DHFA are present with HRP-Compound III (36).  
Hydroxylation of L-tyrosine to L-DOPA by Orf13 in the presence of DHFA is in 
agreement with the HRP peroxygenase activity for aromatic hydroxylation. Although 
molecular oxygen dependent hydroxylation of L-tyrosine by Orf13 in the presence of 
ascorbate or DHFA is observed, it does not appear to be the primary catalytic pathway for 
L-tyrosine hydroxylation since turnover is enhanced 48 and 58 fold, respectively, when 
hydrogen peroxide is provided as a substrate for the hydroxylation reaction (Table 3-2). 
Additionally, similar rate enhancement is observed with hydrogen peroxide in the 



















Orf13  None 0 
Orf13 + H2O2 34 ± 4 100 
Orf13 + H2O2  - O2 33 ± 3 98 
Orf13 + H2O2 + catalase (75 µg/mL)   1.6 ± 0.2 5 
Orf13 + H2O2 + SOD (100 µg/mL) 26.5 ± 0.6 78 
Orf13 + AscA   0.58 ± 0.01 1.7 
Orf13 + AscA  - O2 None 0 
Orf13 + AscA + catalase (75 µg/mL)   0.15 ± 0.01 0.5 
Orf13 + AscA + SOD (100 µg/mL)   0.6 ± 0.1 1.7 
Orf13 + DHFA   0.69 ± 0.06 2 
Orf13 + DHFA  - O2 None 0 
Orf13 + DHFA + catalase (75 µg/mL) None 0 
Orf13 + DHFA + SOD (100 µg/mL) None 0 
a
Abbreviations: Tyrosine Hydroxylase (Orf13), hydrogen peroxide (H2O2), 
molecular oxygen (O2), L-ascorbate (AscA), dihydroxyfumaric acid (DHFA), 
superoxide dismutase (SOD). 
b
Final assay concentrations: 0.5 or 2.5 µM Orf13 (75% heme B occupancy), 5 
mM L-tyrosine in 100 mM sodium phosphate (pH 8.0) at 37°C; 25 mM AscA, 2 
mM DHFA or 500 µM H2O2 as indicated by assay condition. L-DOPA detected 
by L-DOPA colorimetric assay for H2O2 dependent reactions and by HPLC-FLD 
for AscA and DHFA dependent reactions. 
c
kobs measured as µmol of L-DOPA min
-1
; mean and standard deviation reported. 
d
Relative percentage is based on Orf13 + H2O2 condition where maximal 
turnover is observed. 
 
 
Substrate order for catalysis and inactivation by hydrogen peroxide. Heme 
peroxidases typically bind hydrogen peroxide first, although the heme-iron can become 
trapped in a non-productive oxyferrous state (Compound III) during the catalytic cycle 
(31). Characteristic bands for Compound III in HRP include a Soret band at 417 nm and 
Q-bands at 544 nm and 580 nm (75). For Orf13, reversed substrate order of addition is 
necessary for catalysis with maximal tyrosine hydroxylation occurring by pre-incubation 
with L-tyrosine prior to the addition of hydrogen peroxide (Figure 3-3). No turnover is 
observed if hydrogen peroxide is incubated with Orf13 before the addition of L-tyrosine. 
UV-visible absorption scans of Orf13 were taken before and after addition of hydrogen 
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peroxide in the absence of L-tyrosine to investigate whether the lack of catalysis by the 
hydrogen peroxide Orf13 complex is due to formation of Compound III (Figure 3-4). The 
spectrum measured in the presence of hydrogen peroxide shows a significant decrease in 
the Soret band intensity and disappearance of the Q-bands at 503 nm and 630 nm that is 
unlike the characteristic spectrum of HRP-Compound III. Although the formation of 
Compound III has been shown to be stable in HRP for at least five minutes (75), this 
heme-iron species may be transient with Orf13. This may suggest a different hydrogen 




Figure 3-4. UV-visible absorption spectra of Orf13 (4 µM; 100% heme B) in the absence 
(solid line) and presence (dashed line) of 500 µM H2O2 in 100 mM sodium phosphate 
(pH 8.0) at room temperature. Figure was modified from Connor, KL et al (43). 
 
No changes in the heme spectrum were observed by addition of L-tyrosine to 
Orf13. This may indicate that the role of L-tyrosine as the first substrate added is simply 
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to protect Orf13 from hydrogen peroxide inactivation since it does not affect the 
coordination of the heme-iron as observed by the retention of the Q-band at 630 nm 
(Figure 3-5). Interaction of L-tyrosine at the heme edge is consistent as there are no 
changes in the heme spectrum and is evident in heme spectra during catalysis after the 
addition of hydrogen peroxide to Orf13 pre-incubated with L-tyrosine (Figure 3-5).  
 
 
Figure 3-5. UV-visible absorption spectra of Orf13 (100% heme B) with L-tyrosine 
followed by the addition of hydrogen peroxide. Final experimental conditions: 4 µM 
Orf13, 5 mM L-tyrosine, 500 µM H2O2 in 100 mM sodium phosphate (pH 8.0) at room 
temperature. The sample was scanned at 2 minute intervals for 10 minutes after the 
addition of H2O2. Figure was modified from Connor, KL et al (43). 
 
During catalysis the absorbance intensity from 450 nm to 600 nm, most notable in 
the Q-band at 503 nm, increased over time up to 6 minutes, after which no more changes 
were observed. The pattern of absorbance change at 503 nm is similar to what is observed 
for L-DOPA production by the colorimetric assay when Orf13 is pre-incubated with L-
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tyrosine and the reaction initiated with hydrogen peroxide (Figure 3-3). The increase in 
the 503 nm Q-band is similar to a dehaloperoxidase bound complex with 2,4-
dichloroquinone product (76) and may indicate an Orf13 product-complex with L-DOPA.  
Overall, the severe heme bleaching observed with Orf13 indicates a lack of 
enzyme stability due to the high reactivity of the heme-iron when in the presence of 
hydrogen peroxide alone. Inactivation of enzyme activity and/or heme bleaching is not 
uncommon for heme peroxidases (71, 77, 78). Reversed order of substrate addition by 
pre-incubation of Orf13 with L-tyrosine prior to adding hydrogen peroxide prevents heme 
bleaching and is necessary for tyrosine hydroxylation, but does not likely reflect a 
substrate order that is dependent on its catalytic mechanism. While a reversed order of 
substrate addition may be required to limit enzyme inactivation, as found with heme 
peroxidases (71, 77, 78), the catalytic cycle may occur with the normal peroxidase order 
of addition with hydrogen peroxide followed by the aromatic substrate (31, 79).   
Spectroscopy of heme B moiety supports heme peroxidase classification. 
Additional spectroscopic data to characterize the heme B moiety of Orf13 also provide 
support in its classification as a heme peroxidase. This is evident by a Soret band position 
at 421 nm in a reduced-CO (g) spectrum of Orf13 (Figure 3-6). The Soret band position 
in a reduced-CO (g) spectrum is directly related to redox potential of the heme due to the 
interaction between the heme-iron and the proximal (5
th
) ligand that follows the hard-soft 
acid-base (HSAB) principle (80, 81). Historically, this experiment provided the 
cytochrome P450 name originates since the Soret band is observed at or near 450 nm 
(59). This is due to the soft ligand chemistry between the sulfur atom of cysteine and the 
heme-iron. However, heme peroxidases have a histidyl-ligated heme-iron and there is 
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hard ligand chemistry between a nitrogen atom of histidine and the heme-iron. This 
causes the Soret band to be typically observed at or near 420 nm (82). This suggests that 
Orf13 may have a histidyl-ligated heme-iron, especially since no conserved cysteine or 
methionine residues are present in the multiple sequence alignment (Refer to Figure 1-6). 
Furthermore, a low temperature electron paramagnetic resonance (EPR) spectrum of 
ferric-heme Orf13 shows a predominant high spin heme-iron with a g-value centered at 
5.8 (Figure 3-7). Heme peroxidases characteristically have a high spin heme-iron in the 
ferric resting state with the g-values observed between 4.0 and 6.0 (83, 84). 
 
 
Figure 3-6. UV-visible absorption spectrum of ferric-heme Orf13 (solid line) and 
ferrous-CO-heme (g) Orf13 (dashed line) with 100% heme B occupancy in 20 mM Tris-
HCl (pH 8.0), 10 mM imidazole and 10% glycerol. Figure was modified from Connor, 






Figure 3-7. X-band EPR spectrum of ferric-heme Orf13 at 15 K. Experimental 
conditions: 90 µM Orf13 with 50% heme B occupancy (45 µM heme B) in 10 mM 
sodium phosphate (pH 8.0) and 50% glycerol; frequency, 9.478 GHz; microwave power, 
201 µW; modulation frequency, 100 kHz; modulation amplitude, 10.0 G; receiver gain, 5 
x 10
3
. Figure was modified from Connor, KL et al (43). 
 
Conclusion. The identified heme B moiety bound to Orf13 has been established 
as the required cofactor for catalysis with maximal L-tyrosine conversion to L-DOPA 
observed in the presence of hydrogen peroxide. The enzyme catalyzes the ortho-
hydroxylation of L-tyrosine to L-DOPA and has been classified as a heme peroxidase 
based on the requirements of heme B and hydrogen peroxide. This confirms the putative 
role of Orf13 as an L-tyrosine hydroxylase catalyzing the first step in the hydropyrrole 
biosynthetic pathway of the anthramycin (S. refuineus). Pre-incubation of L-tyrosine with 
Orf13 prior to the addition of hydrogen peroxide is required for L-DOPA production. 
However, the enzyme is inactivated by hydrogen peroxide during catalysis. Steady-state 
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kinetic analysis of L-tyrosine hydroxylation revealed similar catalytic efficiency for both 
L-tyrosine and hydrogen peroxide. Similar to heme peroxidases, Orf13 also displays a 
secondary hydroxylation activity of aromatic substrates in the presence of molecular 
oxygen and L-ascorbate or DHFA. This behavior is consistent with peroxygenase activity 
reported with horseradish peroxidase for the hydroxylation of phenol. Spectroscopic data 
from a reduced-CO (g) UV-visible spectrum of Orf13 and EPR of ferric-heme Orf13 are 
consistent with heme peroxidases that have a histidyl-ligated heme-iron. Overall, Orf13 
establishes the first bacterial class of tyrosine hydroxylases and is the first reported heme 
peroxidase to perform hydrogen peroxide dependent aromatic hydroxylation. The novelty 
of this enzyme to catalyze hydrogen peroxide dependent aromatic amino acid 













Chapter 4: Additional characterization of Orf13 as a novel heme 





Orf13 is a heme dependent enzyme that catalyzes the ortho-hydroxylation of L-
tyrosine to L-DOPA in the presence of hydrogen peroxide (Figure 4-1A). Its 
classification as a heme peroxidase is based on the catalytic requirements of heme B and 
hydrogen peroxide. However, the resulting hydroxylated product of L-DOPA is not in 
agreement with the 1-electron oxidized products expected for heme peroxidases. The 
unprecedented novelty of Orf13 to catalyze hydrogen peroxide dependent aromatic amino 
acid hydroxylation presents the potential to establish a different chemical mechanism 
than the mechanisms established for cytochrome P450 enzymes (29, 30, 59, 62) and 
heme peroxidases (29, 31). Cytochrome P450s catalyze oxygen dependent aromatic 
hydroxylation (Figure 4-1B) while heme peroxidases catalyze hydrogen peroxide 
dependent 2-sequential 1-electron transfer reactions (Figure 4-1C). Comparing the net 
reactions and use of the oxygen source by these two distinct types of heme dependent 
monophenol monooxygenases suggest that the tyrosine hydroxylation mechanism for 
Orf13 may fall somewhere in between. The classification of Orf13 as a heme peroxidase 





Figure 4-1. (A) L-Tyrosine hydroxylation catalyzed by Orf13 (S. refuineus). The net 
reactions of (B) cytochrome P450s catalyzing aromatic hydroxylation and (C) heme 
peroxidases catalyzing 2-sequential 1-electron transfer reactions. The oxygen atoms are 
colored red to indicate their use in the respective heme dependent oxidation reaction 
pathways.  
 
Comparative sequence analysis of the highly conserved residues in Orf13 to other 
heme peroxidases based on the spectroscopic data described in Chapter 3, suggests a 
histidyl-ligated heme-iron.  However, Orf13 and its homologs were not initially identified 
as heme dependent peroxidases by BLAST (blastp) analysis nor by the PeroxiBase 
database (85) (http://peroxidase.isb-sib.ch/). Reassessment of the conserved residues in 
the multiple sequence alignment of Orf13 and its homologs (Figure 4-2) reveals some 
similarity to the conserved distal site motif RX2F(W)H characteristic of Class I, II and III 
peroxidases, which are represented by ascorbate peroxidase, Arthromyces ramosus 
peroxidase and HRP, respectively (86-89). The proximal (5
th
) ligand for these heme 
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peroxidases is a highly conserved histidine between 120 to 138 residues away from the 
conserved distal histidine in the RX2F(W)H motif (86-89). 






 has the same 
conserved residues as the distal site RX2F(W)H motif of Class I, II and III heme 
peroxidases. The similarity in these motifs between unrelated enzymes suggests the 
evolutionary adaptation for the utilization of hydrogen peroxide for oxidative reactions 
by heme dependent enzymes. However, residue spacing is different between W72 and 
H76 for Orf13 than the R and F/W of the heme peroxidase distal site motif. Also, two 
highly conserved histidine residues (H140 and H184), one of which may act as the 
proximal (5
th
) ligand for the heme-iron, are closer in sequence to H76 of the potential 
distal site by 63 and 107 residues, respectively. These differences in sequence spacing 
within the potential distal site motif and the proximal histidine may explain why Orf13 
was not recognized as a heme peroxidase and might be required for the different 
reactivity of Orf13 compared to Class I, II and III peroxidases, revealing the existence of 
a new class of bacterial heme peroxidases.  
The overall goal of the work described in this chapter is to establish and define 
the structural features and chemical mechanism of Orf13 by way of 1) identifying 
important residues in the heme active site through crystallography and site-directed 
mutagenesis, 2) evaluating the substrate specificity for aromatic hydroxylation by 






Figure 4-2. Multiple sequence alignment of the Orf13 (residues 42-267) with tyrosine 
hydroxylase homologues from actinomyces. The highly conserved and potential catalytic 







outlined by a blue box. The proposed proximal (5
th
) ligand candidates, H140 and H184, 
are marked by a red diamond.  
 
4.2 Experimental Procedures 
Materials. Oligonucleotide primers for site-directed mutagenesis were purchased 
from Integrated DNA Technologies (San Diego, CA). Protein crystallization kits for 
screening included Wizard I/II and III/IV (Emerald BioSystems; Bedford, MA), Cryos 
Suite (Qiagen; Valencia, CA), PEG II Suite (Qiagen; Valencia, CA) and Index HR2-144 
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(Hampton Research; Aliso Viejo, CA). Carbon monoxide gas, CO (g), was kindly 
provided by the laboratory of Professor Eichhorn (University of Maryland, College Park, 
MD). Substrate analogues (L-phenylalanine, D-tyrosine, DL-m-tyrosine, tyramine, 3-(4-
hydroxyphenyl) propanoic acid and p-cresol), catechol product analogues (dopamine, 3-
(3,4-hydroxyphenyl) propanoic acid and 4-methylcatechol) and all other chemicals were 





O2; 0.27% solution (w/w) with 90% 
18
O atom incorporation) was 
purchased from Icon Isotope Services (Summit, NJ).  
General Methods. Hydrogen peroxide stocks were prepared fresh and quantified 




(71). L-Tyrosine and L-DOPA stocks were 








(70), respectively. All UV-visible absorption spectra or measurement of catechol-nitrite 
complexes for kinetic assays were obtained with a Varian UV-vis Cary100 
Spectrophotometer with Temperature Controller (Walnut Creek, CA). All fluorescence 
spectra or measurements were obtained with a Hitachi F-4500 fluorescence 
spectrophotometer (Hitachi High Technologies Corporation; Tokyo, Japan) using NSG 
precision cell cuvettes (Type 4; 5 mm light path, 5 x 5 mm dimension) and cell mount 
(A23). High performance liquid chromatography was performed with an Agilent 1000 
Series HPLC (Foster City, CA) equipped with a 1100 Series multiple wavelength 
detector and 1200 Series fluorescence detector. Electrospray Ionization Fourier 
Transform Mass Spectrometry (ESI-FT-MS) was performed with an LTQ Orbitrap XL 
(Thermo Scientific; San José, CA) in the Proteomic Core Facility at the University of 
Maryland (College Park, MD). Anaerobic experiments were performed in an 830-ABC 
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series compact glovebox (PLAS-LABS, Inc; Lansing, MI) equipped with a Model 10 Gas 
Analyzer and Digital Heated Fan Box with palladium catalyst bed (Coy Laboratory 
Products, Inc; Grass Lake, MI).  
Equilibrium binding experiments with native WT Orf13. The ligand binding 
assay for imidazole was performed by monitoring a change in the absorbance of the heme 
Soret band (3 µM Orf13 with 100% heme B occupancy in 20 mM sodium phosphate (pH 
8.0) at 25 °C). Ligand binding assays for L-tyrosine, L-DOPA and L-phenylalanine were 
performed by monitoring a change in the heme fluorescence emission of Orf13 (2.5 µM 
Orf13 with 100% heme B occupancy in 20 mM sodium phosphate (pH 8.0) at 25 °C) 
using an excitation wavelength (λEX) at 400 nm and emission wavelength (λEM) at 625 nm 
(90). An excitation slit of 1 nm and emission slit of 20 nm were used to prevent the loss 
of the fluorescence emission signal of the heme from irradiation and heme bleaching. All 
equilibrium binding experiments were performed in triplicate for each ligand. The 
fractional saturation of each equilibrium binding experiment was determined by Equation 
4-1, where Θ is the fractional saturation of the ligand, Xo is the measured signal (λEM at 
625 nm or absorbance maximum of the Soret band, as indicated) for the unbound state of 
Orf13 in the absence of ligand, Xb is the measured signal for the completely bound state 
and X is the measured signal at a given ligand concentration. The dissociation constants 
(KD) of each ligand were calculated by the best fit to the simple binding model (Equation 
4-2) (91) using the software program Prism 4 (GraphPad); Θ is the fractional saturation 
of the ligand, [L] is the concentration of ligand, Bmax is the maximal binding constant 
(limitation: 0 ≤ Bmax ≤ 1) and KD is concentration of ligand required to reach half 




Θ = (X – Xo)/(Xb – Xo) 
Equation 4-2. 
Θ = Bmax x [L]/(KD + [L]) 
Crystallization trials with native WT Orf13. Orf13 (8.9 mg/mL with 100% 
heme B occupancy; 20 mM Tris-HCl (pH 8.0), 10 mM imidazole and 10% glycerol) was 
screened against 5 crystallization kits (Wizard I/II and III/IV (Emerald), Cryos Suite 
(Qiagen), PEG II Suite (Qiagen) and HR2-144 (Hampton Research)) using a Crystal 
Phoenix instrument (ARI, Art Robbins Instruments). Each screen of Orf13 was performed 
using 96 well crystallization trays with 3 enzyme to precipitant solution ratios (1:2, 1:1, 
and 2:1) per well. Trays were sealed and incubated at 20 °C for 1 week before checking 
crystal growth by microscope. Anaerobic screening was performed by the microbatch 
method in an anaerobic glove box. All solutions (oil and kits) were degassed and stored 
within the glove box for 1 week prior to screening. Orf13 purified anaerobically (15.2 
mg/mL with 87% heme B occupancy; 20 mM sodium phosphate (pH 8.0), 80 mM 
sodium chloride and 10% glycerol) was manually screened (1:1; enzyme to precipitant 
solution) per well containing baby oil (10 µL; Johnson & Johnson
®
). The screening 
conditions included Cryos Suite (A1-F12), Index HR2-144 (A1-F12), Wizard III (A1-
C12) and Wizard IV (A1-C12). Plates were placed in a small box containing a wet paper 
towel and incubated for 2 weeks under anaerobic conditions at 25 °C. The plates were 
removed from the glove box to evaluate crystallization under a microscope.  
Site-directed mutagenesis of native Orf13. Mutagenesis of the native Orf13 
construct (pET24a/orf13) for expression in BL21(DE3) E. coli was performed according 
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to the Statagene QuikChange
®
 Site-Directed Mutagenesis Kit protocol (Agilent 
Technologies, Inc; Wilmington, DE). The oligonucleotides to generate variants for the 






) and the potential proximal (5
th
) ligands (H140 
and H184) are listed in Table 4-1. The QuikChange
®
 reactions were digested with DpnI 
for 12 hr at 37 °C and transformed (10 µL aliquot) into GeneHogs (60 µL) (Invitrogen; 
Carlsbad, CA). DNA was isolated by miniprep (Fermentas; Glen Burnie, MD) from 
selected colonies that were resistant to kanamycin and DNA sequencing confirmed 
correct construction of the variants (Table 4-1). Expression of each variant in BL21(DE3) 
E. coli was performed in the presence of ferric iron (III) citrate (500 µM final) under the 
same optimized conditions previously described for native WT Orf13 in Chapter 2. 




 Proposed Role Oligonucleotide Primers (5’ – 3’)
b
 
H76A Catalytic CGAACGAGATCTGCGCGCCGGCGATCCAGC 
GCTGGATCGCCGGCGCGCAGATCTCGTTCG 
H76C Catalytic  CGAACGAGATCTGGCAGCCGGCGATCCAGC 
GCTGGATCGCCGGCTGCCAGATCTCGTTCG 
R71A Catalytic GCCGGCGATCCACGCGTACCAGAACAGCCG 
CGGCTGTTCTGGTACGCGTGGATCGCCGGC 















Variants constructed with the non-fusion tagged Orf13 vector (pET24a/orf13). 
b
Nucleotide mutations are underlined for each variant. 
 
Purification and reduced-CO (g) spectra of Orf13 variants H140C and 
H184C. Three grams of cells expressing Orf13 variant H140C or H184C were purified as 
described for native WT Orf13 using the Ni-Sepharose method (Refer to Chapter 2). The 
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Ni-Sepharose pooled enzyme variants (50 mM sodium phosphate (pH 8.0), 300 mM 
NaCl, 80 mM imidazole and 1 mM DTT) were concentrated to 15 mg/mL, flash frozen 
by liquid nitrogen in droplet form and stored at -80 °C. Purity of the Orf13 H140C and 
H184C variants were greater than 90% as judged by SDS-PAGE. The protein 
concentration was determined using the experimentally determined extinction coefficient 




 (pH 8.0, 25 °C)), the heme B quantitation and 
stoichiometry was measured by the pyridine hemochromagen method (40), and the 
specific activity of Orf13 H140C and H184C was measured using the L-DOPA 
colorimetric assay protocol. The reduced-CO (g) spectrum of the Orf13 H140C variant 
(4.6 µM) with 100% heme B occupancy or the Orf13 H184C variant (17.8 µM) with 36% 
heme B occupancy in 50 mM sodium phosphate (pH 8.0) was measured as described in 
Chapter 3.  
Chemical synthesis, purification and quantitation of dityrosine. Dityrosine 
was chemically synthesized from L-tyrosine as described (92, 93) with a slightly 
modified procedure. A reaction mixture (5 mL) containing L-tyrosine (13 mM), nickel 
(II) acetate (Ni(OAc)2; 26 mM) and potassium monopersulfate (oxone; 12 mM final 
containing 6 mM of potassium peroxymonosulfate, KHSO5) in 10 mM sodium borate 
buffer (pH 10) was stirred for 30 min at room temperature in a glass vial. Sodium 
hydroxide (120 mM final) was added at the start of the reaction to maintain the basicity 
of the solution at pH 10. The reaction mixture was filtered through a MCE filter disc 
(0.45 µm, Millipore; Billerica, MA) to remove solid particles and clarify the reaction 
solution prior to HPLC analysis and purification of dityrosine. An HPLC method to 
separate L-tyrosine and dityrosine was performed as described (94) with direct detection 
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of dityrosine by HPLC-FLD (λEX 325 nm, λEM 410 nm). Reaction aliquots (525 µL) from 
the filtered mixture were treated with 99% TFA (5 µL) and analyzed by HPLC-FLD. 
Dityrosine had an average retention time of 9.9 min and was confirmed by ESI-FT-MS 
with a singly charged mass of 361.13 m/z (exact mass: 360.12). Aliquots of purified 
dityrosine were pooled (~ 4 mL) and lyophilized. The yellowish-orange resin was 
solubilized in deionized water (150 µL) and the final dityrosine concentration was 




 in 25 mM sodium phosphate 
(pH 8.0) (95).  
Dityrosine production assay with native WT Orf13. Two reaction conditions 
were tested to assess the enzymatic production of dityrosine: 1) Orf13 pre-incubation in 
the presence of H2O2 followed by addition of L-tyrosine, and 2) Orf13 pre-incubation 
with L-tyrosine followed by reaction initiation with H2O2. The final assay conditions 
included Orf13 (3 µM; 100% heme B occupancy), L-tyrosine (5 mM final) and H2O2 
(500 µM final) in 100 mM sodium phosphate (pH 8.0). Orf13 was pre-incubated with L-
tyrosine or H2O2 for 5 min at 37 °C followed by addition of the other substrate not 
included during pre-incubation. All assays were performed at 37 °C up to 30 minutes 
with aliquots (525 µL) quenched with 99% TFA (5 µL) at time zero and 30 min. Each 
sample (500 µL) was analyzed by HPLC-FLD as described for detection of dityrosine 
(94). The amount of dityrosine produced by Orf13 was determined based on a calibration 
curve (2 to 20 µM) of chemically synthesized and purified dityrosine. The dityrosine 
standard samples were quantified spectrophotometrically and treated under the same 
assay conditions and sample work up described. The average retention times of the 
chemical standards: L-DOPA (7.3 min), L-tyrosine (8.5 min) and dityrosine (9.9 min). 
65 
 
Assay controls included the same concentrations as the assay samples; 1) Orf13 only, 2) 
Orf13 and L-tyrosine, 3) L-tyrosine with H2O2. 
Aromatic hydroxylation by native WT Orf13 with substrate analogues. 
Production of L-tyrosine was monitored by HPLC-FLD as described (68) for assays with 
L-phenylalanine as the substrate. Orf13 (1.5 µM) was incubated with L-phenylalanine (5 
mM final) for 5 min at 37 °C in 100 mM sodium phosphate (pH 8.0) followed by 
addition of H2O2 (500 µM final) to initiate the reaction. Assays were performed in 
triplicate at 37 °C for 4 min with time points taken at 1, 2, 3, and 4 min. Each aliquot was 
treated as described for the HPLC-FLD method to detect the formation of L-tyrosine 
(Refer to Chapter 3). Assay controls included the same concentrations as the activity 
assay sample in 100 mM sodium phosphate (pH 8.0); 1) Orf13 only, 2) Orf13 and L-
phenylalanine, 3) L-phenylalanine, 4) L-phenylalanine with H2O2, 5) L-tyrosine, and 6) L-
tyrosine (100 µM) with H2O2.  All controls were run in triplicate the same day as the 
assay samples containing Orf13, L-phenylalanine and H2O2, and underwent the same 
method workup described.  
Assays using the substrate analogues DL-m-tyrosine, tyramine, 3-(4-
hydroxylphenyl) propanoic acid and p-cresol were monitored by the L-DOPA 
colorimetric assay for their respective catechol products; L-DOPA, dopamine, 3-(3,4-
hydroxyphenyl) propanoic acid and 4-methylcatechol. Orf13 (1.5 µM) was incubated 
with L-tyrosine (5 mM final) or substrate analogue (5 mM final) for 5 min at 37 °C in 100 
mM sodium phosphate (pH 8.0), followed by addition of H2O2 (500 µM final) to initiate 
the reaction. An aliquot from each substrate analogue reaction was quenched at 2 
minutes, treated under the same colorimetric workup described in Chapter 3 and scanned 
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to obtain a UV-visible absorption spectrum to confirm formation of a catechol-nitrite 
complex. In assays to assess the relative specific activity for substrate selectivity, Orf13 
(1.5 µM) was incubated with L-tyrosine (5 mM final) or substrate analogue (5 mM final) 
for 5 min at room temperature in 100 mM sodium phosphate (pH 8.0), followed by 
addition of H2O2 (250 µM final) to initiate the reaction. Assays were performed in 
triplicate with each substrate at room temperature for 11 min with time aliquots taken at 
1, 3, 6, and 11 min.  
Assays to assess substrate stereoselectivity were performed under normal Orf13 
specific activity conditions:  Orf13 (0.75 µM) was incubated with L-tyrosine (5 mM 
final) or D-tyrosine (5 mM final; 99% optical purity) for 5 min at 37 °C in 100 mM 
sodium phosphate (pH 8.0), followed by addition of H2O2 (500 µM final) to initiate the 
reaction. Assays were performed in triplicate at 37 °C for 4 min with time points taken at 
1, 2, 3, and 4 min. Standard curves of the respective catechol products from 1 to 100 µM 
were prepared the same day for each set of assays. These substrate analogues and 









(70), respectively. Assay controls with a blank solution without 
Orf13 were used to correct for background. Orf13 background control assays were 
carried out with the same concentration of enzyme in the absence of substrates. No 
enzyme background at 500 nm was observed with 1.5 µM Orf13 or less. All controls 
were run in triplicate and in parallel with assay samples and underwent the same 
colorimetric workup described in Chapter 3. 
Identification of the oxygen source for tyrosine hydroxylation. Native WT 
Orf13 (3 µM; 48% heme B occupancy) was pre-incubated in 100 mM sodium phosphate 
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(pH 8.0) with L-tyrosine (5 mM) for 5 min at 37 °C. Hydrogen peroxide (H2O2) or 
18
O-




O atom incorporation) (500 µM final) was 
added to initiate the reaction. All assays were performed at 37 °C for 8 min, at which 
time the entire assay sample (520 µL) was injected into the HPLC instrument and 
analyzed as described for the detection of L-tyrosine and L-DOPA by HPLC-FLD (68). L-
DOPA and L-tyrosine standards had an average retention time of 4.5 and 5.5 minutes, 
respectively. The L-DOPA product from each assay was collected (TR 4.5 min), treated 
with formic acid (1%, v/v) and injected into an ESI-FT-MS to analyze the singly charged 
mass ion of the DOPA product. L-DOPA standard was treated and analyzed accordingly, 
and had an observed singly charged mass of 198.07 m/z (exact mass: 197.07).  
4.3 Results and Discussion 
Equilibrium binding experiments. The dissociation constants (KD) of L-
tyrosine, L-DOPA and L-phenylalanine were determined by equilibrium binding titration 
using the fluorescence properties of heme B bound to Orf13. Typically, the intrinsic 
tryptophan fluorescence of an enzyme (λEX 270 – 290 nm; λEM 340 nm) allows for the 
measurement of ligand dissociation constants. However, this approach could not be used 
since the ligands have similar aromatic structure and fluorescence properties that masked 
the enzyme fluorescence emission signal. Fluorescence properties of heme have been 
used to measure ligand binding by excitation of the Soret band wavelength at 400 nm 
with emission detected at 625 nm (90). Application of this experimental approach to 
Orf13 showed similar excitation and emission spectra of the bound heme B to the 
reported spectra for horseradish peroxidase (90) (See Appendix A-11). Addition of 
phenolic ligands, such as L-tyrosine, to ferric Orf13 quenches the fluorescence emission 
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maxima at 625 nm and 680 nm, but with greater signal change at 625 nm (Figure 4-3A). 
The fluorescence emission maximum at 625 nm was selected to monitor the change in 
emission intensity relative to the amount of titrated ligand (Figure 4-3B) to determine the 
dissociation constant.  
 
 
Figure 4-3. Equilibrium ligand binding experiment for L-tyrosine with Orf13 (100% 
heme B) in 20 mM sodium phosphate (pH 8.0) at 25 °C; (A) The fluorescence emission 
spectra of heme B bound to Orf13 upon titration of L-tyrosine. (B) Direct plot of the 




The dissociation constants for L-tyrosine, L-DOPA, L-phenylalanine and 
imidazole were calculated using the equilibrium titration analysis for simple one site 
binding (Table 4-2; See Appendices A-12 to A-15) (91). The dissociation constant of L-
tyrosine (150 ± 11 µM) is 3 fold lower than the apparent Km (450 ± 40 µM). The binding 
behavior of L-DOPA was poor as it did not display a rectangular hyperbolic curve 
expected for the simple binding model with a calculated dissociation constant of 750 ± 
110 µM (See Appendix A-13). This is 5-fold greater than L-tyrosine and is expected since 
it is the product of the reaction and the heme-iron of Orf13 is in the ferric resting state. 
The dissociation constant of L-phenylalanine (500 ± 160 µM) is 3-fold greater than L-
tyrosine. However, this ligand also did not bind well and displayed a fractional saturation 
curve that deviates from the simple one site binding model (See Appendix A-14).  
 
Table 4-2. Ligand Dissociation Constants for 
Native WT Orf13 
Ligand    KD (µM)
a
 
L-Tyrosine   150 ± 11 
L-DOPA   750 ± 110 
L-Phenylalanine   500 ± 160 
Imidazole
b
 1500 ± 100 
a
Dissociation constants were calculated by 
the best fit line to the simple one site binding 
model (Equation 4-2) (91). 
b
Equilibrium binding assessed by change in 
Soret band absorbance of heme B.  
 
Imidazole does not quench the heme fluorescence signal but induces a change in 
the absorbance of Soret band. The effect of imidazole on the absorption properties of the 
heme was used to measure its dissociation constant. The resulting binding of this ligand 
causes a decrease in the Soret band absorbance and a positional change from 403 nm to 
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406 nm, and changes the relative absorbance intensity of the Q-bands at 543 nm and 567 
nm (Figure 4-4A). This indicates that imidazole is binding in or near the heme active site. 
Imidazole (10 mM) protecting Orf13 during aerobic purification is at a saturating 
concentration approximately 7-fold greater than the imidazole dissociation constant (1.5 
± 0.1 mM) (Figure 4-4B; See Appendix A-15). Orf13 purified in the presence of 
imidazole is dark red while in its absence (protected anaerobically) is dark brown. The 
qualitative color changes of Orf13 in the presence or absence of imidazole are directly 
related to characteristic changes in the heme spectra (Figure 4-4A). These results explain 
the observed chemical protection of Orf13 against auto-oxidative degradation during 
aerobic purification when in the presence of imidazole. The inhibition constant (KI) of 
imidazole for tyrosine hydroxylation by Orf13 was not determined. However, the amount 
of imidazole present in the specific activity assays and steady-state kinetic measurements 
was 40 to 150-fold less (10 to 40 µM final) than the dissociation constant. Therefore, 
inhibition of turnover due to the presence of imidazole is not likely. Overall, the 
dissociation constants for L-tyrosine, L-DOPA, L-phenylalanine and imidazole provide 
useful information for crystallography work involving co-crystallization or crystal 





Figure 4-4. Equilibrium ligand binding experiment for imidazole with Orf13 (100% 
heme B) in 20 mM sodium phosphate (pH 8.0) at 25 °C; (A) Visible absorption spectra of 
heme B bound to Orf13 upon titration of imidazole. Inset: visible absorption spectra of 
the Q-bands in the absence (black trace) or presence of imidazole (red trace; 8.3 mM 
final); (B) Direct plot of the average fractional saturation for imidazole with Orf13 from 
the absorbance maximum of the Soret band (403 nm to 406 nm). 
 
Crystallization of native WT Orf13. Crystallization of Orf13 is critical for the 
identification of active site residues and the proximal (5
th
) heme-iron ligand, as well as to 
determine the overall structural fold of the enzyme.  No crystallization conditions were 
found after aerobic screening of the enzyme with 100% heme B. Only a heavy reddish-
brown precipitant was observed. This indicates that a lack of enzyme stability 
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exacerbated by auto-oxidative degradation is likely preventing crystallization. The 
oxidative degradation of Orf13 has already been well observed and documented since the 
start of its characterization (Refer to Chapter 2). Severe protein degradation is most likely 
related to the reactivity of the heme-iron; however, this auto-oxidative process is not 
completely understood as there is no structural information for this enzyme. Orf13 was 
initially protected by imidazole (10 mM) in the storage condition; however, the final 
concentrations of imidazole during screening fell below saturating levels after mixing 
with the crystallization precipitant (3.3, 5 or 6.6 mM final imidazole at 2, 3 and 4-fold, 
respectively, of its KD). Non-saturating concentrations of imidazole would have likely 
made Orf13 susceptible to auto-oxidative damage, in addition to adding heterogeneity to 
the sample which can prevent crystallization. Specifically, the heterogeneity is within the 
heme active site since imidazole can bind to the heme-iron (Figure 4-4A). This causes a 
slight red shift of the Soret band (from 403 nm to 406 nm) which indicates a change in 
coordination state of the heme-iron. Since stable and active Orf13 can be maintained in 
the absence of oxygen without chemical protectants, anaerobic screening was pursued to 
limit any additional heterogeneity in the sample. However, these efforts also did not 
result in finding a crystallization condition for Orf13. A more rigorous effort will need to 
be pursued to crystallize this difficult enzyme. The key conditions which may prove 
useful in future crystallography work include 1) repeating the aerobic screening with 
saturating amounts of imidazole (30-40 mM) and 2) to anaerobically re-screen and co-
crystallize Orf13 with L-tyrosine (2 mM), particularly if initial crystallization conditions 
are observed from aerobic screening.   
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Mutagenesis of the proposed catalytic residues R71 and H76. The chemical 
mechanism for the heterolytic cleavage of hydrogen peroxide by heme peroxidases 
involves acid/base chemistry between a highly conserved arginine and histidine residue 
located in the active site on the distal side of the heme (31). In Orf13, R71 and H76 are 






) that is 
similar to the distal site motif found in heme peroxidases (RX2F(W)H). If R71 and H76 
in Orf13 are involved in the heterolytic cleavage of hydrogen peroxide, then catalysis 
should be disrupted with variants of these residues. The proposed catalytic role of R71 
and H76 could not be established since neither set of variants were soluble after 
expression. The harvested cells for Orf13 variants H76A, H76C, R71A and R71K 
expressed in BL21(DE3) E. coli with iron (III) citrate were yellow, which indicated the 
absence of bound heme B. Expression of each variant was observed by SDS-PAGE; 
however, all were insoluble after cell lysis by French press. This prevented further 
characterization to assess their proposed catalytic role for the heterolytic cleavage of 
hydrogen peroxide. The lack of red color and protein solubility indicate these variants are 
unable to bind heme B, which was likely due to protein mis-folding from a site-directed 
mutation in a highly conserved region (Figure 4-2). 
Evaluation of the proposed proximal (5
th
) ligand residues H140 and H184. 
The enzyme residue in Orf13 that coordinates the heme-iron may likely be a histidine 
residue based on 1) the  high spin state of the heme-iron in ferric Orf13 observed by low 
temperature EPR, 2) the Soret maximum shift to 421 nm in a reduced-CO (g) UV-visible 
absorption spectrum of Orf13 and 3) the identification of two other highly conserved 
histidine residues (H140 and H184) with similar sequence spacing from the catalytic 
74 
 
distal site histidine found in heme peroxidases (43). If one of these histidine residues is 
the proximal (5
th
) ligand, then this residue can be identified in a reduced-CO (g) UV-
visible absorption spectrum with a cysteine variant. The cysteine variant which 
coordinates the heme-iron will display a Soret maximum shift at or near 450 nm similar 
to thiolate-ligated cytochrome P450s (59).  
The color of harvested cells for both variants, H140C and H184C, expressed in 
BL21(DE3) E. coli with iron (III) citrate were red, similar to WT Orf13. Both were 
soluble upon lysis by French press and were able to intrinsically bind to the Ni-Sepharose 
resin as observed with WT Orf13. Only the Ni-Sepharose purification step was 
performed and resulted in greater than 90% purity as judged by SDS-PAGE. This purity 
was sufficient to evaluate the reduced-CO (g) spectra of the H140C and H184C variants 
(Note: Orf13 variant H76C was not soluble and could not be evaluated as a possible 
proximal (5
th
) ligand residue). The UV-visible absorption spectrum of the purified 
H140C variant resembled the spectrum of purified WT Orf13 (RZ value 1.8) with an RZ 
value ~ 1.6 and confirmed heme B occupancy of 100% (Figure 4-5A). This variant 
displayed catalytic activity for L-DOPA formation with a similar turnover rate (22 ± 2 
min
-1
) as 100% heme B occupied WT Orf13 (28 ± 2 min
-1
). The reduced-CO (g) UV-
visible absorption spectrum of H140C is similar to WT Orf13 with a Soret maximum at 
418 nm (Figure 4-5B), indicating that the native histidine residue is not likely the 
proximal (5
th
) ligand.  
The UV-visible absorption spectrum of the H184C variant appeared to have a 
broader Soret band and only two distinguishable Q-bands (Figure 4-6A). The RZ value 
was 3 fold lower at ~0.6, indicating a low percentage of heme B occupancy that was 
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confirmed as 36% by the pyridine hemochromagen assay. The PPIX stoichiometry was 
not determined but it was anticipated to be roughly 64% to make up the occupancy 
difference. This variant displayed low catalytic activity for L-DOPA formation with a 
turnover rate of 3 ± 1 min
-1
, which likely reflects the low occupancy of heme B. The 
reduced-CO (g) UV-visible absorption spectrum of the H184C variant is also similar to 
WT Orf13 with Soret maxima at 417 nm (Figure 4-6B).  
 
 
Figure 4-5. UV-visible spectra of Orf13 H140C variant; (A) UV-visible absorption 
spectrum of purified H140C variant (100% heme B occupancy) in 50 mM sodium 
phosphate (pH 8.0), 30 mM sodium chloride and 10 mM imidazole; (B) UV-visible 
absorption spectrum of ferric heme Orf13 H140C (black trace) and ferrous-CO (g) heme 




Figure 4-6. UV-visible spectra of Orf13 H184C variant; (A) UV-visible absorption 
spectrum of purified H184C variant (36% heme B occupancy) in 50 mM sodium 
phosphate (pH 8.0), 30 mM sodium chloride and 10 mM imidazole; (B) UV-visible 
absorption spectrum of ferric heme Orf13 H184C (black trace) and ferrous-CO (g) heme 
(red trace) in 50 mM sodium phosphate (pH 8.0) and 12 mM sodium chloride.  
 
The reduced-CO (g) spectra of Orf13 variants H140C and H184C do not appear 
to support Orf13 as a histidyl-ligated heme peroxidase as neither variant displays a Soret 
band shift to 450 nm that is expected for a thiolate-ligated heme-iron. However, the heme 
environment and axial coordination with the heme-iron can limit direct assessment and 
assignment of the proximal (5
th
) residue using this reduced-CO (g) spectroscopic assay. 
77 
 
The ferrous-CO (g) Soret band at or near 450 nm (P450 species) in cytochrome P450 
enzymes can transition to an inactive P420 species (at or near 420 nm) due to the 
proposed formation of a protonated thiol which coordinates the heme-iron (96-99). 
Formation of the P420 species can be pH dependent (98), pressure dependent (99) and/or 
affected by salts such as NaCl (96, 100). The ferrous-CO (g) spectral characteristics of 
the Orf13 H184C variant are very similar to the ferrous-CO (g) spectrum of the P420 
species in P450cam (96), particularly with respect to the height and position of the Soret 
band and the observed Q-bands at 538 nm and 567 nm (Figure 4-6B). Typically, 
reduction of ferric heme to the ferrous state decreases the height of the Soret band since 
the spin state of the iron changes from high to low. This common spectral trend was 
observed in the ferrous-CO (g) spectra of WT Orf13 (Refer to Chapter 3, Figure 3-6) and 
the Orf13 H140C variant (Figure 4-5B). However, the Soret band height of ferrous-CO 
heme in the H184C variant increased (Figure 4-6B) in a similar manner to the formation 
of P420 species observed with P450cam (96). This suggests that the observed species in 
the H184C variant is a P420-like species that originated from a P450 heme species. 
Therefore, H184 is likely the proximal (5
th
) ligand residue. However, direct evidence to 
identify the proximal (5
th
) ligand and to confirm H184 as this ligand from the 
spectroscopic data described will depend on obtaining a crystal structure of native WT 
Orf13. 
Assessment of dityrosine production by Orf13. Classical heme peroxidases 
(horseradish peroxidase (HRP) and myeloperoxidase (MPO)) catalyze 2-sequential 1-
electron transfer reactions with aromatic substrates that non-enzymatically generate 
radically coupled products, such as dityrosine (31, 95, 101) (Figure 4-7). Orf13 is 
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classified as a unique heme peroxidase with a primary catalytic pathway for hydrogen 
peroxide dependent aromatic hydroxylation of L-tyrosine. This enzyme also exhibits 
peroxygenase activity that is similar to HRP by way of a secondary catalytic pathway for 
molecular oxygen dependent tyrosine hydroxylation in the presence of dihydroxyfumaric 
acid or L-ascorbate (Refer to Chapter 3). However, it is not known if Orf13 is able to 
catalyze a 2-sequential 1-electron transfer reaction which can be indirectly observed by 
the non-enzymatic production of dityrosine.  
 
 
Figure 4-7. The 2-sequential 1-electron transfer reaction of horseradish peroxidase and 
myeloperoxidase that promotes non-enzymatic dityrosine formation.   
 
To assess the production of dityrosine by Orf13 in the presence of L-tyrosine and 
hydrogen peroxide, a HPLC separation method was performed as described (94) with 
fluorescence detection added to specifically monitor dityrosine. The fluorescent 
properties of dityrosine (λEX 325 nm, λEM 410 nm) are different from L-tyrosine and L-
DOPA (λEX 281 nm, λEM 314 nm) and allow for greater sensitivity in its detection from 
enzymatic assays where yields may be low (94). L-Tyrosine and L-DOPA standards are 
only detected by absorbance at 280 nm and not λEM 410 nm (See Appendix A-16). The 
retention time of chemically synthesized dityrosine was confirmed at 10 min by ESI-FT-




Figure 4-8. (Panel A) HPLC chromatograms of the dityrosine reaction mixture 
monitored at λEM 410 nm and absorbance at 280 nm; L-Tyrosine (TR 7.9 min). (Panel B) 
ESI-FT-MS of the compound with a retention time of 10 min (indicated by red arrow in 
Panel A) was confirmed as dityrosine by an observed singly charged peak of 361.13 m/z.  
 
Detection of dityrosine from Orf13 reactions was not observed with reaction 
conditions similar to the 4 minute specific activity assay for production of L-DOPA. 
However, if the reaction was allowed to proceed up to 30 minutes, dityrosine was 
detected (Figure 4-9A). As expected the L-DOPA production was observed at 280 nm 
(TR 7.1 min) for Orf13 pre-incubated with L-tyrosine followed by addition of hydrogen 
peroxide. A co-injection of dityrosine standard confirmed dityrosine formation (Figure 4-
9B) and the average amount of dityrosine produced at 30 minutes was 6.5 ± 0.3 µM. A 
second compound detected by fluorescence that eluted at 11.6 minutes had been observed 
in the time zero control for the 30 minute reaction (Figure 4-9A). This indicated it was a 
background species and ESI-FT-MS analysis of this compound was not pursued for its 
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identification. In a control reaction containing L-tyrosine and hydrogen peroxide, 
dityrosine was not formed, demonstrating that the dityrosine observed from the Orf13 
reaction is promoted by the enzyme which had generated tyrosyl radical products that 
coupled together. Furthermore, an enzyme control reaction with Orf13 pre-incubated with 
hydrogen peroxide did not show dityrosine formation by FLD or L-DOPA production at 
280 nm (See Appendix A-17). This confirms inactivation of the enzyme in the absence of 
L-tyrosine, in addition to demonstrating that the main function of Orf13 is tyrosine 
hydroxylation.   
Overall, these data emphasize that the primary function of Orf13 is tyrosine 
hydroxylation. Although the formation of dityrosine is observed with Orf13, its 
production is insignificant over a 30 minute period. This demonstrates that 1-electron 
oxidation of tyrosine by Orf13 is possible, but it is not likely promoted by the same 
enzyme form that catalyzes the production of L-DOPA. Tyrosine hydroxylation by Orf13 
plateaus beyond 4 minutes under the same assay conditions used to assess dityrosine 
production. Inactivation of Orf13 by H2O2 may have generated a non-productive species 
for the tyrosine hydroxylation pathway that is still capable of 1-electron transfer to the 
substrate, L-tyrosine. Some heme peroxidases, such as cytochrome c peroxidase and 
dehaloperoxidase, form an enzyme radical intermediate called Compound ES (67, 76, 
102, 103). This is a protein radical species that is formed when the porphyrin radical of 
Compound I is transferred to an aromatic protein residue in the active site located at the 
edge of the heme. A Compound ES-like species may have been formed in Orf13 during 
catalysis which led to a dead-end form of the enzyme for tyrosine hydroxylation but 
remained competent for the transfer of 1-electron to the L-tyrosine substrate. 
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Accumulation of tyrosyl radical side products likely led to the non-enzymatic formation 
of dityrosine, which could only be detected after prolonged assay times (Figure 4-9A).   
 
 
Figure 4-9. HPLC chromatograms for assessment of dityrosine production by Orf13; 
(Panel A) 30 minute time point of Orf13 (3 µM; 100% heme B) pre-incubated with L-
tyrosine (5 mM final; TR 7.9 min) followed by addition of H2O2 (500 µM final) in 100 
mM sodium phosphate at 37 °C; (Panel B) 30 min time point of Orf13 assay co-injected 
with dityrosine standard (50 µM). Average retention times: L-DOPA (7.1 min), L-
tyrosine (7.8 min) and dityrosine (9.9 min). 
 
 
Substrate specificity of Orf13 for aromatic hydroxylation. Heme peroxidases 
are promiscuous enzymes capable of oxidizing a wide assortment of aromatic substrates. 
Their lack of substrate specificity has been attributed to a larger active site that can 
accommodate various substrates, as well as the presence of additional substrate binding 
locations in the vicinity of the exposed heme edges where the reaction can also occur 
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(104). The substrate analogues L-phenylalanine, D-tyrosine, DL-m-tyrosine, tyramine, 3-
(4-hydroxyphenyl) propanoic acid and p-cresol were selected to test the substrate 
specificity of Orf13 (See Appendix A-18), as well as to evaluate the requirement of 
chemical substituents on the aromatic ring in order for the hydroxylation reaction to 
occur. The para-substituted phenols (tyramine, 3-(4-hydroxyphenyl) propanoic acid and 
p-cresol) were converted by Orf13 in the presence of hydrogen peroxide to their 
respective catechol products, which were detected as colorimetric catechol-nitrite 
complexes using the L-DOPA colorimetric assay (See Appendix A-19). Comparison of 
the relative specific activity of these substrate analogues to L-tyrosine was unsuccessful 
as formation of the product analogues plateaued after the first minute of turnover, while 
L-DOPA formation from L-tyrosine remained linear up to 6 minutes (Figure 4-10). Orf13 
is more susceptible to inactivation by hydrogen peroxide in the presence of these 
substrate analogues than with L-tyrosine. No increase in catechol product formation was 
detected when L-tyrosine was added to the p-cresol reaction after 1 minute, confirming 
the inactivation of Orf13 (data not shown). No L-phenylalanine conversion to L-tyrosine 
was observed using an HPLC-FLD method to detect L-tyrosine, and no L-DOPA 
formation was observed using the L-DOPA colorimetric assay when DL-m-tyrosine was 
provided as a substrate. These results show that the hydroxyl group at the para position 
of the aromatic ring is necessary for hydroxylation since conversion of L-tyrosine, 
tyramine, 3-(4-hydroxyphenyl) propanoic acid and p-cresol to their respective catechol 





Figure 4-10. Progress curves of the aromatic hydroxylation of L-tyrosine and aromatic 
substrate analogues (DL-m-tyrosine, tyramine, 3-(4-hydroxyphenyl) propanoic acid and p-
cresol) by Orf13. Assay conditions: Orf13 (1.5 µM; 48% heme B occupancy), 5 mM L-
tyrosine or substrate analogue, 250 µM H2O2 in 100 mM sodium phosphate (pH 8.0) at 
room temperature. Figure was modified from Connor, KL et al (43). 
 
The substrate stereoselectivity of Orf13 for the amino and carboxyl functional 
groups of tyrosine was evaluated with D-tyrosine (99% optical purity). Orf13 is 
stereoselective for L-tyrosine as turnover with D-tyrosine (0.7 ± 0.1 min
-1
) was negligible 
compared to L-tyrosine (17.0 ± 0.4 min
-1
) for DOPA formation measured by the DOPA 
colorimetric assay (See Appendix A-20). A small amount of DOPA (~ 8 µM) is produced 
in the D-tyrosine reaction after the first minute of turnover, but did not continue to 
increase for the remainder of the time course. This may indicate hydrogen peroxide 
inactivation of Orf13 as previously observed with the other substrate analogs.  
Alternatively, the small turnover observed may have been due to the presence of L-
tyrosine at 1% (50 µM) of the final D-tyrosine concentration in the assay. In either case, 
the results show that Orf13 is selective for L-tyrosine. The stereochemistry of the amino 
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and carboxyl functional groups is important for proper substrate binding and orientation 
of L-tyrosine in the heme active site for catalysis. In addition, the poor binding of L-
phenylalanine (KD = 500 ± 160 µM) and lack of turnover for L-tyrosine production 
implicate the requirement of the hydroxyl group in L-tyrosine for both proper binding in 
the active site and catalysis.  
Identification of the oxygen source for tyrosine hydroxylation. HRP and other 
heme peroxidases such as myeloperoxidase and chloroperoxidase are known to catalyze 
dimerization of aromatic substrates in the presence of hydrogen peroxide by the 2-
sequential 1-electron transfer mechanism (95, 105, 106). However, hydroxylation of 
aromatic amino acids in the presence of hydrogen peroxide by heme peroxidases has not 
been reported (36). These results emphasize the uniqueness of Orf13 for its ability to use 
hydrogen peroxide for aromatic hydroxylation of L-tyrosine. In order to identify the 
source of oxygen found in the enzyme reaction product, L-DOPA, a labeling study using 
H2
18
O2 was performed. The L-DOPA product was analyzed by ESI-FT-MS from an end 
point assay with Orf13 and L-tyrosine in the presence of H2O2 (Figure 4-11A) or H2
18
O2 
(Figure 4-11B). The oxygen originates from H2O2 as there is a 2 amu increase in the 
singly charged mass of the L-DOPA product (200.07 m/z) to indicate the incorporation of 
an 
18





Figure 4-11. HPLC-FLD chromatograms with corresponding ESI-FT-MS spectra of the 
L-DOPA product (TR 4.5 min) from Orf13 reactions catalyzed by (A) H2O2 and (B) 
H2
18
O2; HPLC-FLD λEX 281 nm, λEM 314 nm; L-tyrosine (TR 4.9 min). 
 
Proposed mechanism of L-tyrosine hydroxylation. A possible mechanism of L-
tyrosine hydroxylation for Orf13 may share the initial steps of the classic heme 
peroxidase catalytic cycle up to the formation of Compound I (Scheme 4-1) (95, 105, 
106). Compound I is also an intermediate for aromatic hydroxylation catalyzed by 
cytochrome P450 enzymes for the oxygen dependent reaction and the peroxide shunt 
pathway (29, 62). This intermediate has also been proposed in the hydrogen peroxide 
dependent hydroxylation reactions of heme-thiolate peroxygenases (29, 107). These 
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enzymes function more like heme peroxidases in their use of hydrogen peroxide as the 
oxygen source but are more similar to cytochrome P450s based on their substrate 
specificity and thiolate-ligated heme-iron (29, 107, 108). Orf13 likely represents the first 
heme-histidyl enzyme and serves as a mechanistic bridge between heme peroxidases and 
cytochrome P450 enzymes.  
 





Therefore, subsequent steps after formation of Compound I may be reminiscent of 
the electron rebound mechanism proposed by Groves for cytochrome P450 enzymes 
(Scheme 4-1) (62, 64). Formation of the product complex with the oxygen coordinated to 
the iron (III) center may proceed through a hydroxyl iron (IV) substrate radical complex 
obtained by hydrogen abstraction by Compound I from the substrate (64). The fate of the 
reaction toward hydroxylation rather than 1-electron transfer reactions that can produce 
dityrosine indicates a specific reactivity of the Compound I complex which is controlled 
by steric and electronic interactions in the active site (63, 109). These interactions may 
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significantly reduce the life time of this radical intermediate and/or may stabilize the 
hydroxylation transition state.  
Conclusion. Orf13 is thought to be similar to heme peroxidases with respect to a 
histidyl-ligand heme-iron, which has been suggested as H184 through reduced-CO (g) 
spectral analysis with a H184C variant. This enzyme is also able to catalyze 1-electron 
transfer reactions in a limited capacity that was observed by the marginal non-enzymatic 
production of dityrosine. Conversely, Orf13 is not similar to heme peroxidases based on 
its substrate specificity and stereoselectivity for L-tyrosine. Aromatic hydroxylation with 
para-phenol substrates was observed but the enzyme is more susceptible to hydrogen 
peroxide inactivation. This implicates a catalytic mechanism requiring the para-phenol 
substituent for hydroxylation as no turnover for L-phenylalanine or DL-m-tyrosine was 
observed. The oxygen source for tyrosine hydroxylation was identified as hydrogen 
peroxide with 
18
O-L-DOPA detected by ESI-FT-MS in reactions catalyzed by H2
18
O2. 
This implicates that Orf13 is at a mechanistic intersection between heme peroxidases and 
cytochrome P450 enzymes, and the chemical mechanism of L-tyrosine hydroxylation is 
proposed to proceed through Compound I with direct insertion of an oxygen atom from 









Chapter 5: Conclusions 
 
 
Orf13 is the first functionally identified bacterial tyrosine hydroxylase as well as 
the first heme peroxidase catalyzing aromatic amino acid hydroxylation with hydrogen 
peroxide. The work described in this dissertation provides direct characterization of 
Orf13, a tyrosine hydroxylase, involved in the first step of the hydropyrrole moiety 
biosynthesis of anthramycin (S. refuineus). This enzyme is a heme dependent enzyme 
that requires hydrogen peroxide to catalyze the ortho-hydroxylation of L-tyrosine to L-
DOPA. The catalytic requirements of heme B and hydrogen peroxide classify Orf13 as a 
heme peroxidase. This classification is supported by spectroscopic analyses indicating a 
high spin heme-iron for ferric Orf13 and a histidyl-ligated heme-iron, which has been 
proposed as H184. Orf13 also displays similar catalytic activities observed with heme 
peroxidases; 1) a secondary catalytic pathway for tyrosine hydroxylation which is 
dependent on molecular oxygen and dihydroxyfumaric acid, and 2) 1-electron oxidations 
with hydrogen peroxide resulting in the coupling of tyrosyl radicals that non-
enzymatically produce dityrosine.  
Remarkably, Orf13 shares features found in heme-histidyl peroxidases (29, 31, 
95, 105, 106), heme-thiolate peroxygenases (29, 107, 108), and cytochrome P450 
enzymes (29) (Figure 5-1). In contrast to heme peroxidases yet similar to cytochrome 
P450s, Orf13 is substrate selective for L-tyrosine and its primary function is tyrosine 
hydroxylation. Identification of hydrogen peroxide as the oxygen donor for aromatic 
hydroxylation implicates that this enzyme is at a mechanistic intersection between heme 
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peroxidases and cytochrome P450 enzymes. The chemical mechanism of L-tyrosine 
hydroxylation is proposed to proceed through Compound I, a ferryl heme-iron 
intermediate. This heme intermediate is common in both mechanisms for heme 
peroxidases and cytochrome P450s. Formation of Compound I is expected to share the 
initial catalytic steps of heme peroxidases (29, 31), followed by the hydroxylation of 
tyrosine through an oxygen rebound mechanism proposed for cytochrome P450 enzymes 
(62-64).   
 
 
Figure 5-1. Diagram relating the key features found in heme peroxidases, cytochrome 
P450s, heme-thiolate peroxygenases and Orf13. Text in bold indicates unique attributes 
in contrast to the common qualities of heme peroxidase or cytochrome P450s.    
 
The majority of this dissertation work has been reported in Connor, KL et al (43). 
Unpublished research includes: 1) the identification of hydrogen peroxide as the oxygen 
source with the H2
18
O2 labeling study, 2) site-directed mutagenesis efforts of potential 






, and 3) 
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site-directed mutagenesis and spectroscopic analysis of the proximal (5
th
) ligand 
candidates H140 and H184. A crystal structure of Orf13 could not be obtained at the time 
this dissertation was compiled. This information will be extremely valuable to provide 
direct identification of catalytic residues, the proximal (5
th
) ligand residue and the overall 
active site environment and structural fold. It is hoped that the preliminary results 
described in Chapter 4 will offer supporting evidence and facilitate progress for advanced 
studies once structural information is available. Altogether, this information will continue 
to illustrate the uniqueness of this new class of bacterial tyrosine hydroxylases and guide 
future mechanistic studies.  
At the time this dissertation was compiled and since Orf13 was first reported as a 
novel heme peroxidase (43), only one other enzyme has been reported in the literature as 
a heme peroxidase catalyzing aromatic hydroxylation with hydrogen peroxide (110). 
SmfD, a 3-methyltyrosine hydroxylase from the saframycin A biosynthetic gene cluster 
(Streptomyces lavendulae), was confirmed as a heme dependent enzyme requiring 
hydrogen peroxide to catalyze the production of 3-hydroxy-5-methyltyrosine. This 
enzyme is substrate specific for 3-methyltyrosine than L-tyrosine, and the oxygen source 
was identified as hydrogen peroxide (110). SfmD and Orf13 bear no resemblance to each 
other by global sequence alignment and neither appears as a protein hit when searching 
the protein database using BLAST. This indicates that SfmD and Orf13 are different 
types of heme peroxidases catalyzing hydrogen peroxide dependent aromatic 
hydroxylation. The proximal (5
th
) ligand in SfmD has not been confirmed; however, there 
are conserved cysteine residues which may act as this ligand and further classify this 
enzyme as a heme-thiolate peroxygenase (Figure 5-1). This stresses the novelty of Orf13 
91 
 
as a histidyl-ligated heme peroxidase and the discovery of the first class of bacterial 
tyrosine hydroxylases.  
Prior to the discovery and characterization of Orf13, only the non-heme iron 
pterin or α-KG dependent enzymes and the copper dependent tyrosinases were known to 
specifically catalyze the ortho-hydroxylation of L-tyrosine to L-DOPA (33, 34). Orf13 
expands the known classes of tyrosine hydroxylases and is a new member representing 
the class of histidyl-ligated heme and hydrogen peroxide dependent enzymes. This class 
of bacterial tyrosine hydroxylases has thus far been identified in the biosynthetic 
















A-1. In solution quaternary structure determination of Orf13 by gel filtration  
 
Figure A-1. FPLC chromatogram of molecular weight standards (black trace); aldolase 
(158 kDa; VE 12.1 min), conalbumin (75 kDa; VE 13.5 min), ovalbumin (44 kDa; VE 14.2 
min), and ribonuclease A (13.7 kDa; VE 17.0 min). The quaternary structure of Orf13 (VE 
14.6 min; red trace) was calculated as 37.9 kDa, indicating a monomer based on the 











A-2. MALDI-TOF-MS of Orf13 for protein monoisotopic mass 
The average monoisotopic mass of purifed native Orf13 was measured in 3 
independent samples by MALDI-TOF-MS (Kratos AXIMA-CFR MALDI-TOFMS; 
Kratos Analytical Inc., Manchester, UK) within 10 shots at 110 V with 200 profiles 
collected in a mass range of 0-70,000 m/z. Desalted Orf13 (20 µM) was spotted on the 
MALDI plate using the sandwich method (bottom to top): 1 µL sinapic acid (10 mg/mL 
in 70:30 (v/v) acetonitrile (ACN): 0.1% formic acid), 1 µL sample and 0.75 µL sinapic 
acid (10 mg/mL in 70:30 (v/v) ACN: 0.1% formic acid). Protein standards (10 µM each) 
of apomyoglobin (16,952 Da) and albumin (66,430 Da) (Sigma ProteoMass
TM
 Peptide 
and Protein MALDI-MS Calibration Kit; Cat No. MSCAL1) were also prepared on the 
MALDI plate in the same manner as the Orf13 sample. The observed m/z peaks were 
corrected to match the average mass of each standard sample to calibrate the instrument.   
 
 
Figure A-2. MALDI-TOF-MS of native Orf13 from one independent sample. The singly 
charged peak of 33,690.8 m/z and doubly charged peak 16,893.4 m/z represent the 
monomeric mass of the enzyme (predicted mass of 33,625 Da). The peak of 67,362.9 m/z 
is likely a singly charged dimer species. The average monoisotopic mass of Orf13 




A-3. Pyridine hemochromagen spectra of Orf13 for heme B quantitation 
 
Figure A-3. Visible absorption spectra of the pyridine hemochromagen assay to 
quantitate the amount of heme B bound to Orf13. The basic pyridine solution containing 
Orf13 (black trace) is reduced with dithionite (red trace) to produce the 556 nm band that 

















A-4. HPLC co-injection of protoporphyrin IX (PPIX) with Orf13 
 
Figure A-4. HPLC chromatograms for porphyrin detection: (A) Supernatant of denatured 


















Figure A-5. (A) ESI-MS of peak (TR 44 min, Figure 2-4A) collected from HPLC of the 
denatured Orf13 sample. The singly charged precursor ion m/z 563.5 is the same 
precursor ion m/z observed with PPIX standard sample collected from HPLC at 44 
minutes and is in agreement with the MW of PPIX; (B) The ESI-MS/MS fragmentation 
of m/z 563.5 precursor ion generated a predominant product ion peak at 504.3 m/z. This 
mass is 59 amu less than the precursor ion and corresponds to the loss of –CH2COOH 
from one of the propanoic acid groups of the porphyrin ring. The same fragmentation 
pattern was observed with the PPIX standard sample. Figure was modified from Connor, 










A-6. HPLC-FLD of the Orf13 activity assay in the presence of hydrogen 
peroxide.  
 
Figure A-6. HPLC-FLD chromatograms of the Orf13 activity assay in the presence of 
hydrogen peroxide. Final assay conditions: 2.5 µM Orf13 (76% heme B occupancy), 1 
mM L-tyrosine and 0.1 mM H2O2 in 50 mM sodium phosphate (pH 8.0) at 37 °C. L-
DOPA production was observed by an increase of the peak at 4.6 minutes. Average 
retention times of L-DOPA and L-tyrosine standards are 4.5 and 5.5 minutes, 













A-7. Michaelis-Menten steady-state kinetic analysis of L-tyrosine for L-
tyrosine hydroxylation by Orf13. 
  
    
Figure A-7. Michaelis-Menten curve of L-tyrosine hydroxylation by Orf13 for the 
hydrogen peroxide dependent reaction at fixed variable concentrations of L-tyrosine and a 
fixed H2O2 (500 µM) concentration. Assay conditions: Orf13 was pre-incubated for 5 
min at 37 °C with L-tyrosine followed by addition of H2O2 to initiate the reaction. The 
reaction was carried out for 4 min at 37 °C with L-DOPA formation was measured by the 
L-DOPA colorimetric assay. Statistics of non-linear fitting of the data to the Michaelis-
Menten equation (Equation 3-1) by Prism (GraphPad) are displayed to the right of the 








Substrate: L-Tyrosine Non-linear Fit
 Best-fit values
     KCAT   (min
-1
) 34.55
     KM       (µM) 452.7
Standard Error
     KCAT   (min
-1
) 1.128
     KM       (µM) 50.15
95% Confidence Intervals
     KCAT   (min
-1
) 31.95 to 37.15
     KM       (µM) 337.0 to 568.3
Goodness of Fit
     Degrees of Freedom 8
     R² 0.9799
     Absolute Sum of Squares 12.92
     Sy.x 1.271
Data
     Number of X values 10
     Number of Y replicates 1
     Total number of values 10
     Number of missing values 0
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A-8. Michaelis-Menten steady-state kinetic analysis of hydrogen peroxide at 
2 mM L-tyrosine for L-tyrosine hydroxylation by Orf13. 
 
 
    
 
Figure A-8. Michaelis-Menten curve of L-tyrosine hydroxylation by Orf13 for the 
hydrogen peroxide dependent reaction at fixed variable concentrations of H2O2 and a 
fixed L-tyrosine (2 mM) concentration. Assay conditions: Orf13 was pre-incubated for 5 
min at 37 °C with L-tyrosine followed by addition of H2O2 to initiate the reaction. The 
reaction was carried out for 4 min at 37 °C with L-DOPA formation was measured by the 
L-DOPA colorimetric assay. Statistics of non-linear fitting of the data to the Michaelis-
Menten equation (Equation 3-1) by Prism (GraphPad) are displayed to the right of the 








Substrate: H2O2 Non-linear fit
Best-fit values
     KCAT   (min
-1
) 89.11
     KM       (µM) 1017
Standard Error
     KCAT   (min
-1
) 14.3
     KM       (µM) 264.4
95% Confidence Intervals
     KCAT   (min
-1
) 54.12 to 124.1
     KM       (µM) 370.1 to 1664
Goodness of Fit
     Degrees of Freedom 6
     R² 0.9785
     Absolute Sum of Squares 24.95
     Sy.x 2.039
Data
     Number of X values 8
     Number of Y replicates 1
     Total number of values 8
     Number of missing values 0
100 
 
A-9. Michaelis-Menten steady-state kinetic analysis of hydrogen peroxide at 
0.45 mM and 5 mM L-tyrosine for L-tyrosine hydroxylation by Orf13. 
 
General assay conditions: Orf13 was pre-incubated for 5 min at 37 °C with L-tyrosine 
followed by addition of H2O2 to initiate the reaction. The reaction was carried out for 4 
min at 37 °C with L-DOPA formation was measured by the L-DOPA colorimetric assay. 
 
 
   
Figure A-9A. Michaelis-Menten curve of L-tyrosine hydroxylation by Orf13 for the 
hydrogen peroxide dependent reaction at fixed variable concentrations of H2O2 and a 
fixed L-tyrosine (0.45 mM) concentration. Statistics of non-linear fitting of the data to the 
Michaelis-Menten equation (Equation 3-1) by Prism (GraphPad) are displayed to the 
right of the curve. Steady-state analysis at 0.45 mM L-tyrosine (a non-saturating 
condition) was limited to a maximal H2O2 concentration of 650 µM since inactivation of 




Substrate: H2O2 Non-linear fit
Best-fit values
     KCAT   (min
-1
) 71.65
     KM       (µM) 1380
Standard Error
     KCAT   (min
-1
) 37.62
     KM       (µM) 971.7
95% Confidence Intervals
     KCAT   (min
-1
) -32.78 to 176.1
     KM       (µM) -1318 to 4077
Goodness of Fit
     Degrees of Freedom 4
     R² 0.9486
     Absolute Sum of Squares 11.21
     Sy.x 1.674
Data
     Number of X values 6
     Number of Y replicates 1
     Total number of values 6
     Number of missing values 0
101 
 
   
 
Figure A-9B. Michaelis-Menten curve of L-tyrosine hydroxylation by Orf13 for the 
hydrogen peroxide dependent reaction at fixed variable concentrations of H2O2 and a 
fixed L-tyrosine (5 mM) concentration. Statistics of non-linear fitting of the data to the 
Michaelis-Menten equation (Equation 3-1) by Prism (GraphPad) are displayed to the 





























  1.0 ± 0.3 1.5 ± 0.3 (1.5 ± 0.2) x 10
3
 




Assays were performed at 37 °C with 0.3 – 1 µM Orf13 (75% heme B 
occupancy) in 100 mM sodium phosphate (pH 8.0). L-DOPA formation was 
measured using the L-DOPA colorimetric assay. Data are not normalized to 
heme B occupancy. 
b
Reported steady-state kinetic rate constants for H2O2 (43). 
c








Substrate: H2O2 Non-linear fit
Best-fit values
     KCAT   (min
-1
) 214.4
     KM       (µM) 3472
Standard Error
     KCAT   (min
-1
) 97.7
     KM       (µM) 1906
95% Confidence Intervals
     KCAT   (min
-1
) -24.71 to 453.4
     KM       (µM) -1192 to 8137
Goodness of Fit
     Degrees of Freedom 6
     R² 0.9815
     Absolute Sum of Squares 27.8
     Sy.x 2.153
Data
     Number of X values 8
     Number of Y replicates 1
     Total number of values 8
     Number of missing values 0
102 
 




Figure A-10. HPLC-FLD chromatograms of L-tyrosine hydroxylation by Orf13 in the 
presence of (A) L-ascorbate or (B) dihydroxyfumaric acid. Average retention times of L-
DOPA and L-tyrosine standards are 4.5 and 5.5 minutes, respectively. Figure was 

















Figure A-11. Fluorescence excitation (blue trace) and emission (red trace) spectra of 
Orf13. Sample conditions: 2.5 µM Orf13 (100% heme B) in 20 mM sodium phosphate 
(pH 8.0) at 25 °C. λEX maxima (blue trace): 280 nm, 315 nm, 404 nm, 501 nm, 540 nm 













A-12. Fluorescence equilibrium binding analysis of L-tyrosine with Orf13. 
 
   
Figure A-12. Plot of residuals for the equilibrium binding data across 3 independent 
ligand titration experiments for L-tyrosine with Orf13. The random scattering of the data 
indicates the data fit to the one site binding model (Equation 4-2) is in agreement with the 
model. The statistics of the data (averaged across the 3 independent titration experiments) 











Ligand: L-Tyrosine Non-linear fit
Best-fit values
     BMAX 1.028
     KD  (µM) 149.5
Std. Error
     BMAX 0.02408
     KD  (µM) 11.36
95% Confidence Intervals
     BMAX 0.9762 to 1.080
     KD  (µM) 125.0 to 174.0
Goodness of Fit
     Degrees of Freedom 13
     R² 0.9906
     Absolute Sum of Squares 0.008509
     Sy.x 0.02558
Constraints
     BMAX BMAX > 0.0
     KD KD > 0.0
Data
     Number of X values 15
     Number of Y replicates 1
     Total number of values 15
     Number of missing values 0
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A-13. Fluorescence equilibrium binding data and analysis of L-DOPA with 
Orf13. 
   
Figure A-13A. Equilibrium ligand binding experiment for L-DOPA with Orf13 (100% 
heme B) in 20 mM sodium phosphate (pH 8.0) at 25 °C; (A) The fluorescence emission 
spectra of heme B bound to Orf13 upon titration of L-DOPA; (B) Direct plot of the 
average fractional saturation for L-DOPA with Orf13 based on the change of λEM 625 nm. 
The statistics of the non-linear fit of the data to Equation 4-2, one site binding model for 
dissociation constant of a ligand, using Prism (GraphPad) are displayed to the right of the 
curve.   
 
Ligand: L-DOPA Non-linear fit
Best-fit values
     BMAX 1.657
     KD  (µM) 751.2
Std. Error
     BMAX 0.1435
     KD  (µM) 111.6
95% Confidence Intervals
     BMAX 1.344 to 1.969
     KD  (µM) 507.9 to 994.5
Goodness of Fit
     Degrees of Freedom 12
     R² 0.9885
     Absolute Sum of Squares 0.01208
     Sy.x 0.03172
Constraints
     BMAX BMAX > 0.0
     KD KD > 0.0
Data
     Number of X values 14
     Number of Y replicates 1
     Total number of values 14




Figure A-13B. Plot of residuals for the equilibrium binding data across 3 independent 
ligand titration experiments for L-DOPA with Orf13. The residuals are not randomly 
scattered and display a “U” shaped trend. This indicates that the data fit to the one site 
binding model (Equation 4-2) are not in agreement with this model and the value 

















A-14. Fluorescence equilibrium binding data and analysis of L-
phenylalanine with Orf13. 
 
   
Figure A-14A. Equilibrium ligand binding experiment for L-phenylalanine with Orf13 
(100% heme B) in 20 mM sodium phosphate (pH 8.0) at 25 °C. (A) The fluorescence 
emission spectra of heme B bound to Orf13 upon titration of L-phenylalanine. (B) Direct 
plot of the average fractional saturation for L-phenylalanine with Orf13 based on the 
change of λEM 625 nm. The statistics of the non-linear fit of the data to Equation 4-2, one 
site binding model for dissociation constant of a ligand, using Prism (GraphPad) are 
displayed to the right of the curve.   
 
Ligand: L-Phenylalanine Non-linear fit
Best-fit values
     BMAX 1.429
     KD  (µM) 504.9
Std. Error
     BMAX 0.2143
     KD  (µM) 161.4
95% Confidence Intervals
     BMAX 0.9348 to 1.923
     KD  (µM) 132.6 to 877.2
Goodness of Fit
     Degrees of Freedom 8
     R² 0.9619
     Absolute Sum of Squares 0.03687
     Sy.x 0.06789
Constraints
     BMAX BMAX > 0.0
     KD KD > 0.0
Data
     Number of X values 10
     Number of Y replicates 1
     Total number of values 10




Figure A-14B. Plot of residuals for the equilibrium binding data across 4 independent 
ligand titration experiments for L-phenylalanine with Orf13. The residuals are not 
randomly scattered and display a “W” shaped trend. This indicates that the data fit to the 
one site binding model (Equation 4-2) are not in agreement with this model and the value 

















A-15. Absorbance equilibrium binding data and analysis of imidazole with 
Orf13. 
 
    
 
Figure A-15. Plot of residuals for the equilibrium binding data across 3 independent 
ligand titration experiments for imidazole with Orf13. The random scattering of the data 
indicates the data fit to the one site binding model (Equation 4-2) is in agreement with the 
model. The statistics of the data (averaged across the 3 independent titration experiments) 










Ligand: Imidazole Non-linear fit
Best-fit values
     BMAX 1.157
     KD  (mM) 1.514
Std. Error
     BMAX 0.01449
     KD  (mM) 0.07081
95% Confidence Intervals
     BMAX 1.124 to 1.190
     KD  (mM) 1.354 to 1.675
Goodness of Fit
     Degrees of Freedom 9
     R² 0.9983
     Absolute Sum of Squares 0.001481
     Sy.x 0.01283
Constraints
     BMAX BMAX > 0.0
     KD KD > 0.0
Data
     Number of X values 11
     Number of Y replicates 1
     Total number of values 11
     Number of missing values 0
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A-16. HPLC-FLD chromatogram of dityrosine, L-tyrosine and L-DOPA for 
the assessment of dityrosine production with Orf13.  
 
 
Figure A-16. HPLC chromatograms of chemical standards to assess dityrosine 
production by Orf13. The linear gradient of methanol with 0.1% TFA is shown in blue. 
Chemical standards: 100 µM L-DOPA (TR 7.3 min), 100 µM L-tyrosine (TR 8.6 min) and 








A-17. HPLC-FLD chromatogram of Orf13 pre-incubated with H2O2 for 
assesment of dityrosine production.   
 
 
Figure A-17. HPLC chromatograms for assessment of dityrosine production by Orf13. 
Assay condition: 30 minute time point of Orf13 (3 µM; 100% heme B) pre-incubated 
with hydrogen peroxide (500 µM final) followed by addition of L-tyrosine (5 mM final; 








A-18. Substrate analogues to evaluate substrate requirements for aromatic 
hydroxylation by Orf13.   
 
 
Figure A-18. Chemical structures of L-tyrosine (1) and substrate analogues (2-7) used to 
evaluate the substrate specificity of the aromatic hydroxylation reaction by Orf13; D-
tyrosine (2), DL-m-tyrosine (3), L-phenylalanine (4), tyramine (5), 3-(4-hydroxyphenyl) 














A-19. Catechol-nitrite complexes of substrate analogues hydroxylated by 
Orf13.   
 
 
Figure A-19. Visible absorption spectra of catechol-nitrite complexes for catechol 
product formation by the aromatic hydroxylation of L-tyrosine and phenol substrate 
analogues by Orf13 in the presence of hydrogen peroxide. Final assay conditions: 1.5 µM 
Orf13 (48% heme B occupancy), 5 mM L-tyrosine or substrate analogue, 500 µM H2O2 
in 100 mM sodium phosphate (pH 8.0). All reactions were performed at 37 °C, quenched 
at 2 minutes and underwent the DOPA colorimetric assay work described in Chapter 3. 
The substrate analogue 3-(4-hydroxyphenyl) propanoic acid is abbreviated as 3-HPPA. 















A-20. Turnover comparison of D vs L-tyrosine to assess substrate 




Figure A-20. Progress curves of tyrosine hydroxylation for L-tyrosine (●) or D-tyrosine 
(♦) by Orf13. Assay conditions: 0.75 µM Orf13 (48% heme B), 5 mM (L or D) tyrosine 
and 500 µM H2O2 in 100 mM sodium phosphate (pH 8.0) at 37 °C. Orf13 was pre-
incubated with tyrosine for 5 min at 37 °C followed by addition to H2O2 to initiate the 
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